{"meta":{"query_hash":"5ce50c55e25f","filters":{"venue":"Immunotherapy"},"cohort_total":51,"direct_labels_cover":0,"predictions_cover":51,"exported":51,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5ce50c55e25f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Immunotherapy"},"results":[{"id":"W1979255880","doi":"10.2217/imt.10.44","title":"Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy","year":2010,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Immunotherapy; Dendritic cell; Immunology; Viral vector; Immune system; Cancer immunotherapy; Antigen; Biology; Antigen-presenting cell; T cell; Autoimmunity; Cytotoxic T cell; Medicine; In vitro; Recombinant DNA","score_opus":0.018322650537083374,"score_gpt":0.3438783695124331,"score_spread":0.32555571897534974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979255880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003327193,0.9964898,0.0010848943,0.00022033807,0.00019519345,0.000009734129,0.000016315395,0.000024548312,0.0016264261],"genre_scores_gemma":[0.0012576231,0.9960776,0.001292331,0.0001920112,0.00014785763,0.000012199929,0.00003799805,0.0000040162327,0.0009782774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998111,0.000027512977,0.00002318779,0.00002879296,0.00009192314,0.000017496055],"domain_scores_gemma":[0.99981743,0.00007255998,0.000024712472,0.000008544296,0.000052370564,0.000024546292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008208198,0.0008797609,0.0010873817,0.0018347332,0.00025371672,0.0009919612,0.0008194994,0.0011319353,0.0020729424],"category_scores_gemma":[0.00039165476,0.00032063527,0.00039860635,0.0020568331,0.0005379269,0.0015650748,0.00059537153,0.0018423479,0.0023952287],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066542,0.00011639568,0.0001783479,0.00658932,0.000053500487,0.00034963823,0.00006255897,0.000517084,0.01540759,0.008390834,0.012100755,0.95616746],"study_design_scores_gemma":[0.000032217504,0.00011114854,0.00047319807,0.0009970025,0.00006226075,0.0016944872,0.000040964514,0.00023848687,0.0058427732,0.003319202,0.9871645,0.00002382817],"about_ca_topic_score_codex":0.0006426751,"about_ca_topic_score_gemma":0.00073623913,"teacher_disagreement_score":0.0020729424,"about_ca_system_score_codex":0.0008115871,"about_ca_system_score_gemma":0.00072488753,"threshold_uncertainty_score":0.006934643},"labels":[],"label_agreement":null},{"id":"W1982443638","doi":"10.2217/imt.14.108","title":"Lentiviral Vectors in Cancer Immunotherapy","year":2015,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Canada Research Chairs; University of Toronto","funders":"","keywords":"Immunotherapy; Viral vector; Cancer immunotherapy; Cancer; Insertional mutagenesis; Immune system; Genetic enhancement; Vector (molecular biology); Medicine; Computational biology; Gene delivery; Effector; Clinical trial; Biology; Immunology; Cancer research; Bioinformatics; Gene; Genome; Genetics","score_opus":0.03454148207282977,"score_gpt":0.34331361838432595,"score_spread":0.3087721363114962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982443638","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0150790755,0.82731473,0.10869226,0.0046099233,0.0024109555,0.00032361128,0.00048814376,0.0010751582,0.040006228],"genre_scores_gemma":[0.15388583,0.7066689,0.08472737,0.0035959424,0.0021321983,0.00062231673,0.0015726688,0.00028613047,0.04650867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999469,0.00012219779,0.000045332396,0.000057635676,0.0002619973,0.000043931417],"domain_scores_gemma":[0.9998474,0.00004850893,0.000032760898,0.000016048118,0.000031514977,0.000023758828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010966486,0.0005795946,0.00069927785,0.0009628517,0.00035101603,0.0013918338,0.0005872992,0.0011110323,0.0022254197],"category_scores_gemma":[0.00047139404,0.000344668,0.0003490261,0.0009539211,0.0007344711,0.0011436243,0.0006680507,0.0027835655,0.0020071713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024529296,0.00023335878,0.00051167666,0.0019332751,0.00006352714,0.0006951512,0.0003487914,0.0014939291,0.21290962,0.10398302,0.02236635,0.65521604],"study_design_scores_gemma":[0.00010330785,0.00061775977,0.0005650499,0.00059595704,0.00006550247,0.0019518654,0.000058844627,0.0017289479,0.09536043,0.02140051,0.8775003,0.000051516152],"about_ca_topic_score_codex":0.00045963153,"about_ca_topic_score_gemma":0.00040344038,"teacher_disagreement_score":0.0022254197,"about_ca_system_score_codex":0.00083508,"about_ca_system_score_gemma":0.0007008534,"threshold_uncertainty_score":0.007444799},"labels":[],"label_agreement":null},{"id":"W1993673970","doi":"10.2217/imt.14.122","title":"Bidirectional Interactions of NK Cells and Dendritic Cells in Immunotherapy: Current and Future Perspective","year":2015,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada)","funders":"","keywords":"Crosstalk; Immunotherapy; Immune system; Tumor microenvironment; Cancer immunotherapy; Dendritic cell; Innate immune system; Biology; Acquired immune system; Cell biology; Immunology; Physics","score_opus":0.025132914531614585,"score_gpt":0.3209390407875841,"score_spread":0.2958061262559695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993673970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007567711,0.99837995,0.00016538877,0.00038409635,0.00034725195,0.000002247874,0.0000064720894,0.0000057723482,0.000633068],"genre_scores_gemma":[0.0005914814,0.99798137,0.00023911208,0.0002815809,0.00040666462,0.0000045826773,0.000014004482,0.000001328631,0.0004798279],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998348,0.00003228052,0.000026427067,0.000029047105,0.00005502351,0.000022381717],"domain_scores_gemma":[0.9996846,0.00014390169,0.00004086148,0.000009873976,0.000076457465,0.00004426264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064022245,0.0006767081,0.0010051788,0.0012874962,0.0002522608,0.0010747792,0.000685429,0.0013427294,0.002985699],"category_scores_gemma":[0.00053354556,0.0002448369,0.00041532508,0.0014640731,0.00048593222,0.002007238,0.0007789492,0.0019334934,0.0016963829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071696006,0.00006898464,0.00020255032,0.012710962,0.000062405095,0.00019480319,0.00006848351,0.0003796696,0.0028632686,0.006838526,0.034033082,0.9425056],"study_design_scores_gemma":[0.000010276442,0.00006525731,0.00043497697,0.0020778673,0.00006969158,0.0011236363,0.000056957153,0.00009763592,0.00047578366,0.0030563385,0.9925154,0.000016336015],"about_ca_topic_score_codex":0.00047978153,"about_ca_topic_score_gemma":0.000864935,"teacher_disagreement_score":0.002985699,"about_ca_system_score_codex":0.0005727196,"about_ca_system_score_gemma":0.0010566169,"threshold_uncertainty_score":0.009988129},"labels":[],"label_agreement":null},{"id":"W2007718183","doi":"10.2217/imt.13.81","title":"Ustekinumab for the Treatment of Crohn‘s Disease","year":2013,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Genentech; ActoGeniX; Zalicus; Janssen Biotech; Wyeth","keywords":"Ustekinumab; Medicine; Crohn's disease; Psoriasis; Monoclonal antibody; Disease; Immunology; Immune system; Monoclonal; Crohn disease; Inflammatory bowel disease; Antibody; Tumor necrosis factor alpha; Internal medicine; Adalimumab","score_opus":0.09589915221036092,"score_gpt":0.41507802521478165,"score_spread":0.3191788730044207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007718183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019942217,0.9983504,0.000083672305,0.00014866907,0.00010797324,0.000005369563,0.000012748037,0.000008754055,0.001082985],"genre_scores_gemma":[0.0010612385,0.9978389,0.00015391111,0.00015966035,0.000097896154,0.00000591398,0.00002818772,0.0000016068806,0.000652675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980575,0.00003403692,0.00002758771,0.00002840503,0.00008693025,0.000017387376],"domain_scores_gemma":[0.9998528,0.000060306844,0.000032092936,0.000004584332,0.000032144762,0.000018099492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041315658,0.0006312164,0.0010839078,0.0022511305,0.0002452661,0.0005746035,0.0005791862,0.0007866035,0.003911452],"category_scores_gemma":[0.00041552784,0.00018163222,0.0005171411,0.0020196126,0.0003224488,0.0007806363,0.0005183057,0.0015444314,0.0028379695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008090131,0.000064420594,0.00011261165,0.00777321,0.00007096579,0.00016526891,0.0000333576,0.000122033314,0.0015873702,0.000856846,0.016886609,0.9722464],"study_design_scores_gemma":[0.00005690441,0.00015063041,0.0010039437,0.0035371492,0.00014787143,0.0022881804,0.000048388145,0.00006564408,0.000674404,0.00089355983,0.9911179,0.00001535611],"about_ca_topic_score_codex":0.0005485924,"about_ca_topic_score_gemma":0.0013893163,"teacher_disagreement_score":0.003911452,"about_ca_system_score_codex":0.0003447694,"about_ca_system_score_gemma":0.0005194264,"threshold_uncertainty_score":0.013085127},"labels":[],"label_agreement":null},{"id":"W2043429701","doi":"10.2217/imt.13.141","title":"Employing an IL-23 p19 Vaccine to Block IL-23 Ameliorates Chronic Murine Colitis","year":2013,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Colitis; Medicine; Immunology; In vivo; Interleukin 23; Splenocyte; Pathogenesis; Inflammatory bowel disease; In vitro; Peptide vaccine; Interleukin; Antibody; Cytokine; Disease; Internal medicine; Epitope; Biology","score_opus":0.006629204937353886,"score_gpt":0.248728499099141,"score_spread":0.2420992941617871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043429701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991569,0.0017720357,0.005048226,0.00018622188,0.0001035718,0.00011753158,0.00015258533,0.00017091028,0.00087989785],"genre_scores_gemma":[0.9909073,0.001751356,0.005142533,0.00012005561,0.000059800765,0.00011074648,0.00032437342,0.000023210934,0.0015605505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989784,0.000011376965,0.000010098117,0.000016861739,0.000026470278,0.000037349408],"domain_scores_gemma":[0.99990225,0.000012719725,0.00003579467,0.000008525087,0.000011340541,0.00002941636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012607577,0.0005179632,0.00032990228,0.00029668483,0.00009997616,0.00021682565,0.00021380497,0.00039098907,0.00089946826],"category_scores_gemma":[0.00009494132,0.00010697393,0.0002283392,0.00012442381,0.000241291,0.00020805778,0.0001367261,0.0009235787,0.00025253897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026690855,0.00044831133,0.0001520303,0.00008475862,0.0000098636765,0.00006736165,0.0000089505065,0.00020896556,0.9947798,0.00006662991,0.00006363372,0.003842772],"study_design_scores_gemma":[0.00025238856,0.0066667767,0.0021464059,0.000024339945,0.00007450716,0.00038146426,0.00001667699,0.0015887026,0.98609436,0.00007088325,0.0026773727,0.000006181088],"about_ca_topic_score_codex":0.00022588106,"about_ca_topic_score_gemma":0.0003970717,"teacher_disagreement_score":0.00089946826,"about_ca_system_score_codex":0.00015254023,"about_ca_system_score_gemma":0.00025845598,"threshold_uncertainty_score":0.0030090213},"labels":[],"label_agreement":null},{"id":"W2067278548","doi":"10.2217/imt.11.25","title":"Research Highlights: Do Conventional Treatments for HPV-Positive Head and Neck Cancers Elicit Immunotherapeutic Type Responses?","year":2011,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; HPV vaccines; Cancer; Human papillomavirus; Head and neck cancer; MEDLINE; Family medicine; Oncology; Internal medicine; Cervical cancer; HPV infection; Biology","score_opus":0.10979874981573376,"score_gpt":0.4235713409828063,"score_spread":0.31377259116707257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067278548","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094910135,0.0021660868,0.00013425568,0.9845344,0.0077493507,0.000013895329,0.00003419863,0.00001605829,0.0044027255],"genre_scores_gemma":[0.018612275,0.0060746865,0.00065269653,0.8815734,0.0822362,0.00006749993,0.000056077846,0.000021306541,0.010705891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973936,0.0010921689,0.00030886978,0.00023885368,0.00060683594,0.00035954462],"domain_scores_gemma":[0.99305904,0.0046212855,0.0005610582,0.0002052243,0.0009996603,0.000553799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028342283,0.0005667893,0.0010251905,0.00036150735,0.0020080062,0.0026845376,0.0009363403,0.024217106,0.008637206],"category_scores_gemma":[0.015703753,0.0003712603,0.0007363612,0.00050040334,0.002120518,0.0036411781,0.0010872149,0.015816595,0.0047639525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018891883,0.00012708557,0.002066733,0.00029443164,0.000022603088,0.006439402,0.00028714715,0.0001864963,0.0010559832,0.0062161046,0.9225127,0.060602393],"study_design_scores_gemma":[0.00023512467,0.00033279604,0.0019974266,0.00045974762,0.000055434542,0.009391354,0.0011353892,0.0006395137,0.0006958015,0.018402701,0.9666013,0.00005334806],"about_ca_topic_score_codex":0.0012802521,"about_ca_topic_score_gemma":0.0023450626,"teacher_disagreement_score":0.024217106,"about_ca_system_score_codex":0.0034522964,"about_ca_system_score_gemma":0.0024150547,"threshold_uncertainty_score":0.028894365},"labels":[],"label_agreement":null},{"id":"W2069156224","doi":"10.2217/imt.12.27","title":"Research Highlights: Highlights from the Latest Articles in Immunotherapy","year":2012,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Flora (microbiology); Immunology; Immune system; Autoimmunity; Disease; Gut flora; Biology; Nod; Microbiology; Medicine; Diabetes mellitus; Bacteria; Internal medicine; Genetics","score_opus":0.03316066186204686,"score_gpt":0.31498712821296493,"score_spread":0.28182646635091807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069156224","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044086666,0.033298045,0.00033675643,0.7591549,0.2013024,0.000029620143,0.00010261846,0.00006950761,0.005265309],"genre_scores_gemma":[0.0029291208,0.016776197,0.00041821157,0.3264346,0.6449057,0.000042057753,0.00006874431,0.00004245178,0.008382866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970927,0.0006809184,0.00033044667,0.00041963652,0.001080988,0.0003952938],"domain_scores_gemma":[0.9935562,0.0029293653,0.00047979705,0.00020331828,0.0015525069,0.0012787501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034468,0.0019869788,0.0026725496,0.0010440686,0.002491598,0.0059591676,0.0022316214,0.019935483,0.008149319],"category_scores_gemma":[0.01224823,0.0006777062,0.0016252672,0.0011862993,0.0026502586,0.0037853352,0.0015294476,0.030415978,0.005943314],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001266006,0.000043622258,0.00017562944,0.00017293263,0.000027038885,0.0011791154,0.00002654538,0.000067167086,0.00024568744,0.001192287,0.9765954,0.020147966],"study_design_scores_gemma":[0.00018499988,0.00008542963,0.00077003374,0.00028460007,0.000065345004,0.0016637284,0.0001319464,0.0002256759,0.00028791255,0.00419989,0.9920622,0.000038335693],"about_ca_topic_score_codex":0.0010766551,"about_ca_topic_score_gemma":0.002770536,"teacher_disagreement_score":0.019935483,"about_ca_system_score_codex":0.003498724,"about_ca_system_score_gemma":0.00205652,"threshold_uncertainty_score":0.02726221},"labels":[],"label_agreement":null},{"id":"W2070064055","doi":"10.2217/imt.09.80","title":"Immunization of Newborn and Adult Mice with Low Numbers of BCG Leads to Th1 Responses, Th1 Imprints and Enhanced Protection Upon BCG Challenge","year":2009,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Vaccination; Medicine; Immunization; Immunology; Immune system; Context (archaeology); Tuberculosis; Immunity; Biology; Pathology","score_opus":0.013538066028322032,"score_gpt":0.30396912302094264,"score_spread":0.2904310569926206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070064055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968753,0.0011273082,0.0007224353,0.000101147525,0.000032113832,0.000038180267,0.0001831049,0.000043724576,0.00087662577],"genre_scores_gemma":[0.9962733,0.0006589125,0.0008375914,0.00015587818,0.000035356785,0.000051362837,0.00026717418,0.000009789643,0.0017106708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997665,0.00007059261,0.000024873718,0.000035608893,0.0000310382,0.00007132801],"domain_scores_gemma":[0.9996892,0.000046648052,0.00007268766,0.000049853603,0.000017302646,0.0001243355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061498955,0.00030004914,0.00044804902,0.00030179718,0.00016256457,0.00022707217,0.00020680191,0.0003882084,0.0012710165],"category_scores_gemma":[0.00031608835,0.00017052398,0.000156201,0.00012675142,0.0002871704,0.00027393314,0.00017549522,0.0010157687,0.00028703353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008381435,0.0016202325,0.003565659,0.00012907472,0.000026693164,0.00014777012,0.00011356507,0.00015548551,0.97120607,0.0002449478,0.00032641258,0.014082598],"study_design_scores_gemma":[0.0009532743,0.04940495,0.049970753,0.000048839,0.000115745155,0.0013709201,0.00009397136,0.0010131848,0.8922761,0.00021600832,0.0045150607,0.000021244992],"about_ca_topic_score_codex":0.0002343967,"about_ca_topic_score_gemma":0.00044239263,"teacher_disagreement_score":0.0012710165,"about_ca_system_score_codex":0.00017573837,"about_ca_system_score_gemma":0.00015917882,"threshold_uncertainty_score":0.004251957},"labels":[],"label_agreement":null},{"id":"W2097078544","doi":"10.2217/imt.12.17","title":"Distinct Roles of Dendritic and B Cells in the Activation of Naive CD4 <sup>+</sup> T Cells","year":2012,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Cell biology; Chemistry; Molecular biology; Biology; Immunology","score_opus":0.007320964166931451,"score_gpt":0.24076332085394234,"score_spread":0.23344235668701088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097078544","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066705532,0.07393402,0.0016278172,0.04686142,0.8608567,0.00011477358,0.00017728485,0.00015566616,0.009601763],"genre_scores_gemma":[0.027512332,0.08435871,0.0008700723,0.021473933,0.8257758,0.00010944309,0.00020413267,0.00009499962,0.039600622],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990514,0.00012964105,0.00011761219,0.00015204669,0.00042027546,0.00012896],"domain_scores_gemma":[0.99786514,0.0007043806,0.000120967685,0.000051868225,0.00075202034,0.00050557253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026676431,0.0009456064,0.0009722091,0.0009770637,0.000864857,0.0019989603,0.0011359828,0.0026398732,0.005536795],"category_scores_gemma":[0.0022729924,0.0004489817,0.0007966851,0.00036967295,0.0013489254,0.0013705544,0.0005298258,0.0049275677,0.0018453231],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014147437,0.00013810284,0.0007484804,0.002302194,0.000100295714,0.0013725366,0.00017052644,0.00021258536,0.011190866,0.0041100327,0.85846907,0.1197706],"study_design_scores_gemma":[0.00014366291,0.000249536,0.0018301569,0.00042873487,0.00010130937,0.001168247,0.00014706167,0.00028070778,0.0052356403,0.0018810899,0.98850596,0.000027853117],"about_ca_topic_score_codex":0.00035905294,"about_ca_topic_score_gemma":0.0007934281,"teacher_disagreement_score":0.005536795,"about_ca_system_score_codex":0.00112612,"about_ca_system_score_gemma":0.001051422,"threshold_uncertainty_score":0.018522441},"labels":[],"label_agreement":null},{"id":"W2106760394","doi":"10.2217/imt.09.33","title":"Conference Scene: 3Rd Keystone Symposium On T Regulatory Cells","year":2009,"lang":"en","type":"article","venue":"Immunotherapy","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"T-cell receptor; Biology; Antigen; Immunology; T cell; Immune system","score_opus":0.01104180238505264,"score_gpt":0.23039033689177657,"score_spread":0.21934853450672392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106760394","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038460114,0.076102205,0.0017037438,0.15006526,0.7129186,0.0003354672,0.0009192231,0.0003169247,0.053792562],"genre_scores_gemma":[0.025182296,0.047829583,0.0018043906,0.04943221,0.29649767,0.00057116564,0.001854046,0.00038250588,0.5764461],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864537,0.00014440436,0.00004739126,0.00018980146,0.00045461455,0.0005183564],"domain_scores_gemma":[0.9976313,0.00015867202,0.00008835032,0.00005618342,0.00057104684,0.0014943411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003578313,0.002679707,0.0014009965,0.0019277986,0.0025393495,0.0053329514,0.0018484136,0.008026313,0.06878497],"category_scores_gemma":[0.0018939882,0.00062233995,0.0020369038,0.0009415039,0.0008627348,0.0023626306,0.004117732,0.008885458,0.024165705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002150542,0.00006588328,0.00012942066,0.00018402086,0.000022639475,0.00011970013,0.000027283793,0.0000896345,0.0011680374,0.0010953004,0.97823775,0.018645242],"study_design_scores_gemma":[0.000055041626,0.000109680805,0.0008038796,0.00016047621,0.000029172343,0.00010095908,0.00007964949,0.000088105706,0.00072985416,0.000982527,0.99683976,0.000020833728],"about_ca_topic_score_codex":0.001959662,"about_ca_topic_score_gemma":0.007500092,"teacher_disagreement_score":0.06878497,"about_ca_system_score_codex":0.0023501609,"about_ca_system_score_gemma":0.0040528825,"threshold_uncertainty_score":0.23010862},"labels":[],"label_agreement":null},{"id":"W2111454565","doi":"10.2217/imt.10.40","title":"T-Cell-Directed Treatment Strategies for Type 1 Diabetes and the Confounding Role of Inflammation","year":2010,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Type 2 diabetes; Inflammation; Confounding; Medicine; Diabetes mellitus; Type 1 diabetes; Bioinformatics; Immunology; Internal medicine; Biology; Endocrinology","score_opus":0.00426918085693779,"score_gpt":0.2497773023748755,"score_spread":0.24550812151793772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111454565","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011160859,0.13700618,0.0010420203,0.06099652,0.7889594,0.00007814559,0.00011206197,0.00017239028,0.010517189],"genre_scores_gemma":[0.0063775415,0.13735496,0.00063168403,0.034929667,0.7898508,0.00007982532,0.0001088526,0.00008194698,0.030584726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914145,0.00017537967,0.00009851381,0.00011181978,0.0003738936,0.00009900101],"domain_scores_gemma":[0.9971361,0.0014105798,0.00015615445,0.000095353025,0.0008449692,0.00035687737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024018257,0.0016285798,0.0010204182,0.0010092907,0.0006665095,0.0021375674,0.0013371342,0.0035581312,0.013451029],"category_scores_gemma":[0.0038011055,0.00036859963,0.0009722933,0.00047267327,0.0012057199,0.0020727748,0.0005514052,0.0069217053,0.0042671505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032115495,0.00007087045,0.0001175836,0.0010100992,0.0000438161,0.00035656666,0.00003387641,0.00012883647,0.0009523014,0.0024605142,0.9238438,0.07066048],"study_design_scores_gemma":[0.0000850713,0.00009413364,0.00024191466,0.00029738483,0.00004271559,0.00051401404,0.000029070416,0.0001400084,0.0004759952,0.0012388731,0.9968292,0.00001155618],"about_ca_topic_score_codex":0.00026391682,"about_ca_topic_score_gemma":0.00066508306,"teacher_disagreement_score":0.013451029,"about_ca_system_score_codex":0.0008421454,"about_ca_system_score_gemma":0.0006799761,"threshold_uncertainty_score":0.04499823},"labels":[],"label_agreement":null},{"id":"W2133116144","doi":"10.2217/imt.09.40","title":"Immunotherapy as a Strategy for Treatment of Leishmaniasis: a Review of the Literature","year":2009,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Research on Leishmaniasis Studies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Manitoba Health Research Council","keywords":"Leishmaniasis; Medicine; Immunotherapy; Immunology; Intensive care medicine; Drug resistance; Drug; Immune system; Biology; Pharmacology","score_opus":0.0728975426469038,"score_gpt":0.4127452399516908,"score_spread":0.33984769730478703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133116144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011976605,0.99914396,0.000058438378,0.00010920267,0.00009738342,0.000004169389,0.000010659057,0.0000036768556,0.000452642],"genre_scores_gemma":[0.00045606014,0.9990664,0.0001413121,0.00007557878,0.000084096675,0.000003974528,0.000011902957,5.5309954e-7,0.00016018382],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998307,0.000031252275,0.000037538655,0.000030788473,0.000058658738,0.000011008288],"domain_scores_gemma":[0.99971265,0.00014451018,0.00005454836,0.0000071892578,0.00005687098,0.00002420532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004036874,0.0008795287,0.0016463803,0.003160593,0.0002872857,0.0008325906,0.0008372384,0.0008252131,0.0045711296],"category_scores_gemma":[0.0005793019,0.00022857117,0.00044062836,0.0036705432,0.00043020898,0.0013041862,0.0003751549,0.00089026825,0.0017994908],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010745336,0.0001377425,0.00031903153,0.046037875,0.00013766608,0.0006891239,0.00008840205,0.00032008585,0.0019506472,0.0015707341,0.025925364,0.9227159],"study_design_scores_gemma":[0.000054388434,0.0002522938,0.002586743,0.015253075,0.0004632415,0.0077318586,0.00022204906,0.00013386285,0.0007644411,0.0018948873,0.9706095,0.000033769775],"about_ca_topic_score_codex":0.0008902938,"about_ca_topic_score_gemma":0.001671881,"teacher_disagreement_score":0.0045711296,"about_ca_system_score_codex":0.000402187,"about_ca_system_score_gemma":0.0009011629,"threshold_uncertainty_score":0.015291989},"labels":[],"label_agreement":null},{"id":"W2135975326","doi":"10.2217/imt.14.66","title":"Vedolizumab for Ulcerative Colitis and Crohn’s Disease: Results and Implications of GEMINI Studies","year":2014,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Vedolizumab; Ulcerative colitis; Medicine; Inflammatory bowel disease; Internal medicine; Gastroenterology; Crohn's disease; Placebo; Maintenance therapy; Disease; Immunology; Pathology; Chemotherapy","score_opus":0.014533153546715452,"score_gpt":0.2979342926323513,"score_spread":0.28340113908563586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135975326","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12674081,0.8365893,0.0009180978,0.012591935,0.00072531926,0.00058190426,0.00097030535,0.000039635695,0.020842584],"genre_scores_gemma":[0.48857284,0.48184216,0.0041893115,0.01304971,0.002660941,0.00046313088,0.002574055,0.00009472828,0.006553219],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99533457,0.0026576265,0.0005702265,0.00032364958,0.00076903397,0.00034493115],"domain_scores_gemma":[0.98663956,0.007193908,0.0014655705,0.00066459336,0.0027757848,0.0012605519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021482702,0.0008314984,0.0017625265,0.00086744566,0.00033982232,0.0017612057,0.0008658783,0.0011291633,0.002401843],"category_scores_gemma":[0.010285165,0.00023970057,0.002072757,0.001215895,0.0010117033,0.001487154,0.0005137388,0.0017661798,0.0005641177],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07387974,0.004353695,0.018176623,0.005454854,0.0034825073,0.0004978972,0.00057718134,0.0009679472,0.013284796,0.0036130506,0.009948567,0.86576307],"study_design_scores_gemma":[0.044448804,0.17459357,0.26402345,0.0126118045,0.020151317,0.0025525086,0.0012733791,0.0015417993,0.020492952,0.0049845083,0.45307106,0.0002548043],"about_ca_topic_score_codex":0.002048548,"about_ca_topic_score_gemma":0.0031422249,"teacher_disagreement_score":0.021482702,"about_ca_system_score_codex":0.001593438,"about_ca_system_score_gemma":0.0017383727,"threshold_uncertainty_score":0.11361277},"labels":[],"label_agreement":null},{"id":"W2156823146","doi":"10.2217/imt.13.123","title":"Evolution of Oncolytic Viruses: Novel Strategies for Cancer Treatment","year":2013,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncolytic virus; Biology; Immune system; Cancer; Virotherapy; Immunotherapy; Virus; Immunology; Immunogenic cell death; Innate immune system; Virology; Cancer research; Genetics","score_opus":0.08584175302475491,"score_gpt":0.41542203599673644,"score_spread":0.3295802829719815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156823146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013588002,0.9403334,0.029446807,0.0035822634,0.0012702735,0.0001227864,0.0002329421,0.000195474,0.011228024],"genre_scores_gemma":[0.10035682,0.85745347,0.025956346,0.0026995777,0.00078164355,0.00021661805,0.0006102905,0.00007051806,0.01185474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997098,0.000075636395,0.000015360136,0.00005078128,0.00010651702,0.00004181096],"domain_scores_gemma":[0.99987936,0.000035352088,0.000019462228,0.000009995507,0.000034806926,0.00002109601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007260868,0.00041603934,0.00061001943,0.0007772097,0.0002340798,0.0011184616,0.00049341,0.00076409825,0.0019755682],"category_scores_gemma":[0.00043233033,0.00024300639,0.00063086604,0.00044062707,0.0005470797,0.0012517185,0.000713213,0.0023545767,0.0009789743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004494197,0.0003651633,0.0009747113,0.004799292,0.00025155413,0.0006173018,0.0004384915,0.0032217111,0.19939603,0.058564056,0.022190617,0.70873165],"study_design_scores_gemma":[0.0000965563,0.00093540916,0.0010000279,0.0007789161,0.00014182464,0.0016883351,0.000094718984,0.0020838387,0.044846714,0.013883953,0.93439245,0.000057341043],"about_ca_topic_score_codex":0.0006064519,"about_ca_topic_score_gemma":0.00089062424,"teacher_disagreement_score":0.0019755682,"about_ca_system_score_codex":0.00077681284,"about_ca_system_score_gemma":0.00047333218,"threshold_uncertainty_score":0.0066089034},"labels":[],"label_agreement":null},{"id":"W2162451701","doi":"10.2217/imt.14.7","title":"Alemtuzumab for the Treatment of Relapsing–Remitting Multiple Sclerosis","year":2014,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alemtuzumab; Relapsing remitting; Multiple sclerosis; Medicine; Fingolimod; Oncology; Internal medicine; Immunology","score_opus":0.20229048024819685,"score_gpt":0.4048349850202537,"score_spread":0.20254450477205688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162451701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005882563,0.99941516,0.000038554146,0.000060410977,0.000041004212,0.000005163488,0.000011465908,0.000003973857,0.0003654967],"genre_scores_gemma":[0.00058961025,0.9988808,0.00010265441,0.000085906046,0.00003997136,0.0000061332157,0.00002197793,9.418176e-7,0.00027202285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972063,0.00006291978,0.00005352904,0.000038082177,0.000104578336,0.00002019378],"domain_scores_gemma":[0.99976283,0.00011121485,0.000053670137,0.0000074128416,0.000046838184,0.000018125014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066100346,0.00080706243,0.0016722701,0.004100539,0.00029899913,0.00074816693,0.00074977893,0.0008777986,0.0051564667],"category_scores_gemma":[0.0007317973,0.00023841369,0.0008546009,0.003675471,0.00035944217,0.00088377733,0.00073034706,0.0013503483,0.0020023887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001298827,0.00007965386,0.00012397525,0.044237256,0.00025903402,0.00017899863,0.00006750484,0.00019208457,0.0014159229,0.0015555164,0.020428536,0.9313317],"study_design_scores_gemma":[0.000084071726,0.0001326278,0.0011088889,0.01339892,0.00049430475,0.0019239412,0.00006115468,0.00005493069,0.0005814646,0.0013413456,0.98079896,0.000019337955],"about_ca_topic_score_codex":0.001273238,"about_ca_topic_score_gemma":0.0022377295,"teacher_disagreement_score":0.0051564667,"about_ca_system_score_codex":0.0005255057,"about_ca_system_score_gemma":0.0010322826,"threshold_uncertainty_score":0.017250061},"labels":[],"label_agreement":null},{"id":"W2513976653","doi":"10.2217/imt-2016-0070","title":"Controlling Inflammation: A Superior Way to Control TB","year":2016,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Tuberculosis; Medicine; Human immunodeficiency virus (HIV); MEDLINE; Mycobacterium tuberculosis; Family medicine; Library science; Internal medicine; Pathology; Computer science; Biology","score_opus":0.011924646046051014,"score_gpt":0.3318239860897753,"score_spread":0.3198993400437243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513976653","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013844255,0.01608967,0.00009818016,0.04877023,0.9343961,0.000013158452,0.000030939784,0.000028061004,0.00055996457],"genre_scores_gemma":[0.00014749604,0.007578803,0.00008035045,0.024621032,0.9648173,0.0000141284945,0.0000135037135,0.000016181184,0.0027112514],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847074,0.0038899065,0.002760638,0.0013579741,0.0064914273,0.0007926147],"domain_scores_gemma":[0.95326626,0.023033319,0.0038091154,0.0014165605,0.013228025,0.0052466774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01760275,0.0064239134,0.008101482,0.0055998657,0.0037976746,0.012670615,0.0062314062,0.03525906,0.009847522],"category_scores_gemma":[0.052358497,0.0025611718,0.004308737,0.002789166,0.0050557964,0.009722529,0.003865502,0.04585841,0.010758305],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006380433,0.000020701575,0.00003122022,0.00063450687,0.00007525584,0.00008837799,0.000015107022,0.000027700553,0.00004158195,0.00052159827,0.990715,0.007765117],"study_design_scores_gemma":[0.00020285588,0.00006376864,0.00030317935,0.0013517499,0.00028026834,0.00029987248,0.000049355836,0.00019358785,0.00010996169,0.0028820352,0.99422026,0.000043150205],"about_ca_topic_score_codex":0.002448746,"about_ca_topic_score_gemma":0.007309339,"teacher_disagreement_score":0.03525906,"about_ca_system_score_codex":0.005535112,"about_ca_system_score_gemma":0.006545293,"threshold_uncertainty_score":0.093093395},"labels":[],"label_agreement":null},{"id":"W2550798570","doi":"10.2217/imt-2016-0079","title":"Double-Blind, Placebo-Controlled, 1:1 Randomized Phase III Clinical Trial Of Immunoxel Honey Lozenges as an Adjunct Immunotherapy in 269 Patients with Pulmonary Tuberculosis","year":2016,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Bee Products Chemical Analysis","field":"Agricultural and Biological Sciences","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Adjunct; Medicine; Placebo; Double blind; Lozenge; Clinical trial; Immunotherapy; Tuberculosis; Randomized controlled trial; Phases of clinical research; Pulmonary tuberculosis; Internal medicine; Pathology; Cancer","score_opus":0.02854180778147574,"score_gpt":0.30122457999191543,"score_spread":0.2726827722104397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550798570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885436,0.0020503441,0.00061504723,0.00047702625,0.0004941841,0.0061831977,0.0005513313,0.00009256108,0.000992544],"genre_scores_gemma":[0.9831457,0.0019004325,0.0016695368,0.001071662,0.00071060885,0.007574455,0.0007017124,0.00002047921,0.0032055045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995326,0.00021698597,0.00003060642,0.000089747846,0.00004023974,0.00008984709],"domain_scores_gemma":[0.9992779,0.0001796257,0.00015544909,0.000048042806,0.000050024933,0.00028892732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013504911,0.0017237469,0.0033523252,0.00038591662,0.00068077527,0.00092061306,0.00098471,0.0016407305,0.0076120156],"category_scores_gemma":[0.0013980151,0.0009268643,0.00079703104,0.00033456742,0.0014636626,0.0008785483,0.0004965388,0.0023307898,0.0012914201],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97019887,0.014611397,0.00069162855,0.0004086604,0.00019202699,0.000045138702,0.000048154667,0.0001601486,0.0038001987,0.00005990449,0.0005546704,0.00922921],"study_design_scores_gemma":[0.8835363,0.11442059,0.0011687462,0.000013669728,0.00007981253,0.00002428735,0.000017263552,0.00018686807,0.00021937264,0.00004655877,0.00027906903,0.0000074536383],"about_ca_topic_score_codex":0.00058865506,"about_ca_topic_score_gemma":0.0015969084,"teacher_disagreement_score":0.0076120156,"about_ca_system_score_codex":0.0005947644,"about_ca_system_score_gemma":0.0011679983,"threshold_uncertainty_score":0.025464714},"labels":[],"label_agreement":null},{"id":"W2792760898","doi":"10.2217/imt-2017-0162","title":"CD19-specific Chimeric Antigen Receptor-Modified (CAR)-T cell Therapy for the Treatment of Chronic Lymphocytic Leukemia in the Ibrutinib Era","year":2018,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Medicine; Chimeric antigen receptor; Leukemia; Oncology; Cancer; Immunology; Internal medicine; Immunotherapy","score_opus":0.026547901132691322,"score_gpt":0.3216215715794757,"score_spread":0.29507367044678434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792760898","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007993652,0.020743083,0.00019064435,0.03400834,0.9436322,0.000020278054,0.000046062556,0.000057505764,0.0012220738],"genre_scores_gemma":[0.00082559785,0.018390965,0.00015408112,0.026646236,0.94649315,0.00002126353,0.0000368899,0.00002190399,0.0074097565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801314,0.0004317697,0.00030546883,0.00021473957,0.0008714313,0.00016330776],"domain_scores_gemma":[0.99348444,0.0030582256,0.00043648863,0.00012639898,0.0019498607,0.00094449165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004162932,0.0022928088,0.0025602242,0.0015388868,0.0015027383,0.0035194578,0.0028958472,0.01066234,0.0060366686],"category_scores_gemma":[0.010034883,0.000702402,0.0019354351,0.00071586046,0.0013123344,0.003075279,0.00084717374,0.015565452,0.00428877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014732117,0.000028487128,0.00002709766,0.00044563977,0.00003573587,0.00016207957,0.000010745747,0.00005115316,0.00014580993,0.00054084184,0.98232025,0.016084893],"study_design_scores_gemma":[0.00026627502,0.00012118475,0.00027776608,0.00044547935,0.00011759191,0.0004425033,0.000023173554,0.00025007472,0.00025601167,0.0009853331,0.9967913,0.000023205026],"about_ca_topic_score_codex":0.001239493,"about_ca_topic_score_gemma":0.0030559362,"teacher_disagreement_score":0.01066234,"about_ca_system_score_codex":0.0022989616,"about_ca_system_score_gemma":0.0018402387,"threshold_uncertainty_score":0.022015989},"labels":[],"label_agreement":null},{"id":"W2804640215","doi":"10.2217/imt-2018-0003","title":"Ragweed Sublingual Tablet Immunotherapy: Part II – Practical Considerations and Pertinent Issues","year":2018,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ragweed; Sublingual immunotherapy; Medicine; Slit; Allergy; Clinical trial; Dermatology; Immunotherapy; Allergic asthma; Asthma; Allergen immunotherapy; Intensive care medicine; Allergen; Immunology; Internal medicine; Immune system","score_opus":0.08254104935116863,"score_gpt":0.3923671133085607,"score_spread":0.3098260639573921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804640215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007975551,0.99844176,0.000047375634,0.0006015576,0.00028588527,0.000005588971,0.000012765628,0.0000022391719,0.00052309106],"genre_scores_gemma":[0.000709913,0.99761117,0.00013953309,0.00059471984,0.00043437787,0.000009139358,0.000021224367,0.0000016452544,0.00047822256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99953854,0.000115122544,0.00011412354,0.00005719986,0.00014369981,0.00003134814],"domain_scores_gemma":[0.9988808,0.0006649976,0.00017219568,0.00002769039,0.00021681262,0.00003750256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886729,0.00055075047,0.0012657221,0.0021708927,0.00028881922,0.0014411589,0.00067877304,0.001301193,0.0054100165],"category_scores_gemma":[0.0020898131,0.00028378027,0.00080494373,0.0020846913,0.0005219347,0.0020568282,0.00063449115,0.0015307808,0.0013843345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008165728,0.000072060575,0.00019887723,0.084700696,0.00014358165,0.0004892783,0.0002798759,0.00024191554,0.0021270192,0.005193607,0.06611467,0.8403568],"study_design_scores_gemma":[0.000014527251,0.00007404825,0.0007423411,0.017474692,0.00013844726,0.002153139,0.00014398873,0.000056720055,0.00027539514,0.0018828836,0.977029,0.000014827839],"about_ca_topic_score_codex":0.0010797982,"about_ca_topic_score_gemma":0.0021206904,"teacher_disagreement_score":0.0054100165,"about_ca_system_score_codex":0.00048088448,"about_ca_system_score_gemma":0.0015486821,"threshold_uncertainty_score":0.018098295},"labels":[],"label_agreement":null},{"id":"W2908942081","doi":"10.2217/imt-2018-0167","title":"Immune Checkpoint Inhibitors and Non-Small-Cell Lung Cancer Management: 2018 Update","year":2019,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Pembrolizumab; Atezolizumab; Nivolumab; Medicine; Lung cancer; Oncology; Internal medicine; Docetaxel; Avelumab; Ipilimumab; Cancer; Immunotherapy","score_opus":0.005902408804642505,"score_gpt":0.2602707838035951,"score_spread":0.2543683749989526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908942081","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008455106,0.06807377,0.00027320423,0.05826679,0.87122613,0.000017752469,0.00007564811,0.000055969,0.0019261516],"genre_scores_gemma":[0.0007005686,0.04713677,0.00025722518,0.041983847,0.9046177,0.000021018821,0.000071725255,0.000027032593,0.005184126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976059,0.00054506987,0.0004244596,0.00024209902,0.001015306,0.00016723236],"domain_scores_gemma":[0.98934585,0.0048951274,0.00095054886,0.00013266713,0.0036813465,0.0009944296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045645125,0.0018195498,0.002560754,0.002338967,0.0011242047,0.003916559,0.0018862841,0.0065999874,0.0038754386],"category_scores_gemma":[0.014422704,0.00062929513,0.0015323668,0.0011718197,0.001161344,0.0028874455,0.0012177472,0.013725748,0.003812478],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006540905,0.000017276456,0.0000651228,0.00052745367,0.000033802407,0.000089089765,0.000009857769,0.000035800516,0.00006071067,0.00042180423,0.96859723,0.030076439],"study_design_scores_gemma":[0.00011276878,0.000058878635,0.00040531985,0.0013322531,0.00014824378,0.00042867174,0.000034703655,0.00018899288,0.00010717622,0.00085329486,0.99630654,0.00002313756],"about_ca_topic_score_codex":0.0013808025,"about_ca_topic_score_gemma":0.0047050933,"teacher_disagreement_score":0.0065999874,"about_ca_system_score_codex":0.0021742822,"about_ca_system_score_gemma":0.0024108056,"threshold_uncertainty_score":0.024139702},"labels":[],"label_agreement":null},{"id":"W2921861485","doi":"10.2217/imt-2018-0186","title":"Toxicity Patterns Associated with Chemotherapy/Immune Checkpoint Inhibitor Combinations: A Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Meta-analysis; Chemotherapy; Toxicity; Medicine; Immune checkpoint; Immune system; Immunotherapy; Oncology; Immunology; Internal medicine","score_opus":0.0886360825971064,"score_gpt":0.34861315145748456,"score_spread":0.2599770688603782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921861485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051143654,0.99335325,0.0005177046,0.00015243191,0.000080632584,0.00009037512,0.00043468017,0.00001376877,0.00024270918],"genre_scores_gemma":[0.21070917,0.7838062,0.0023049428,0.0008780832,0.0002942115,0.00040216057,0.0011763799,0.000041369196,0.00038756925],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99311346,0.00355367,0.0016995805,0.0008171921,0.0006334778,0.00018254585],"domain_scores_gemma":[0.9864225,0.009986774,0.0022917471,0.00041972072,0.0007416336,0.00013762506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010167819,0.0025894556,0.011480485,0.005504114,0.00039218419,0.0024970758,0.0013417841,0.0014111424,0.002916934],"category_scores_gemma":[0.01733529,0.0011209704,0.03626701,0.0061520645,0.00035615158,0.0011570829,0.0010903327,0.001430688,0.000265091],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002072573,0.000025566316,0.008111488,0.15182072,0.81633675,0.00012649783,0.00003253772,0.00084033,0.00027259116,0.00010572364,0.0006675666,0.01958759],"study_design_scores_gemma":[0.00034543892,0.00016805046,0.0048524844,0.008738088,0.9835992,0.00016136553,0.000019878144,0.00022011442,0.00010727643,0.00019095752,0.0015824444,0.000014704167],"about_ca_topic_score_codex":0.0029119982,"about_ca_topic_score_gemma":0.0067535406,"teacher_disagreement_score":0.011480485,"about_ca_system_score_codex":0.0014557601,"about_ca_system_score_gemma":0.0013738419,"threshold_uncertainty_score":0.053773224},"labels":[],"label_agreement":null},{"id":"W2978287760","doi":"10.2217/imt-2018-0035","title":"Atezolizumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient with Urothelial Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Sarcoidosis and Beryllium Toxicity Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Atezolizumab; Medicine; Sarcoidosis; Malignancy; Mediastinal lymph node; Lymph node; Lymph node biopsy; Biopsy; Mediastinal lymphadenopathy; Pathology; Carcinoma; Radiology; Immunotherapy; Cancer; Internal medicine; Nivolumab; Metastasis","score_opus":0.0186478648614335,"score_gpt":0.27772663420479604,"score_spread":0.25907876934336255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978287760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905343,0.0021754934,0.0007183067,0.001047888,0.000110150955,0.00007434474,0.00006760423,0.000052898355,0.0052189045],"genre_scores_gemma":[0.9988041,0.0003247898,0.00012900028,0.00023549415,0.00010936383,0.0000050778326,0.000026889955,0.0000041003477,0.00036117973],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997081,0.00005221997,0.00004279926,0.000067085406,0.00003567878,0.000094088224],"domain_scores_gemma":[0.99905354,0.000390011,0.00013090833,0.000081044964,0.000052075506,0.00029245537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041322352,0.0006529385,0.00094615977,0.00079740095,0.0013537077,0.0007662865,0.00032782016,0.0024262236,0.0013938001],"category_scores_gemma":[0.0019911712,0.0005277261,0.00057325343,0.0004860508,0.00067248417,0.00076315086,0.0005091667,0.0012486165,0.0004178406],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020663897,0.000146888,0.034910202,0.000046400462,0.00001648179,0.95949185,0.0004162102,0.00010629866,0.0020013934,0.00012577866,0.00020107676,0.0023307046],"study_design_scores_gemma":[0.0000817311,0.00050657714,0.03344425,0.000024486499,0.000041493196,0.96332186,0.00017928712,0.00050757435,0.0008219259,0.0001336379,0.0009213235,0.000015842483],"about_ca_topic_score_codex":0.00079831097,"about_ca_topic_score_gemma":0.0008546623,"teacher_disagreement_score":0.0024262236,"about_ca_system_score_codex":0.00056349003,"about_ca_system_score_gemma":0.00033362082,"threshold_uncertainty_score":0.0046626925},"labels":[],"label_agreement":null},{"id":"W3041847701","doi":"10.2217/imt-2020-0153","title":"How COVID-19 Affects Patients Receivingc anticytokine and JAK Inhibitors in Rheumatology and Dermatology","year":2020,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Western University","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Rheumatology; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Dermatology; Internal medicine; Immunology; Virology","score_opus":0.017185335524739165,"score_gpt":0.280928578010123,"score_spread":0.26374324248538383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041847701","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008857315,0.003830267,0.0001249629,0.968567,0.008942014,0.000017699236,0.000081472106,0.000022419597,0.009556741],"genre_scores_gemma":[0.11399601,0.0050341384,0.0005056536,0.8387856,0.02783507,0.000037022768,0.000078333855,0.000017147378,0.013711103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915934,0.00032669533,0.00010374769,0.000084071704,0.00018666251,0.00013950755],"domain_scores_gemma":[0.99835336,0.00087695493,0.00009744807,0.000043129967,0.00032660307,0.00030248452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009638407,0.0002522466,0.0004570157,0.00040652795,0.0019492881,0.001073787,0.00034357767,0.010152105,0.003394792],"category_scores_gemma":[0.0069590327,0.00017446613,0.00052894175,0.00038881207,0.0007200035,0.001114082,0.0004609213,0.0053881467,0.0014582056],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037675412,0.00034168063,0.033197757,0.00018191745,0.00006096418,0.041755553,0.00083713554,0.00021218568,0.001560919,0.0051117274,0.84460753,0.07175597],"study_design_scores_gemma":[0.0005677674,0.00069083483,0.042932034,0.0012347957,0.00017637745,0.14122193,0.0033599304,0.0021781651,0.0011770418,0.02410142,0.7822085,0.00015130611],"about_ca_topic_score_codex":0.008015784,"about_ca_topic_score_gemma":0.010939422,"teacher_disagreement_score":0.010152105,"about_ca_system_score_codex":0.0021626963,"about_ca_system_score_gemma":0.0012960883,"threshold_uncertainty_score":0.015938222},"labels":[],"label_agreement":null},{"id":"W3047233339","doi":"10.2217/imt-2020-0158","title":"Romosozumab in the Treatment of Osteoporosis","year":2020,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"Amgen","keywords":"Sclerostin; Osteoporosis; Medicine; Bone resorption; Bone mineral; Bone Density Conservation Agents; Wnt signaling pathway; Internal medicine; Bioinformatics; Chemistry; Signal transduction; Biology; Biochemistry","score_opus":0.0488655667525898,"score_gpt":0.34608488723398706,"score_spread":0.29721932048139726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047233339","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031073724,0.9904619,0.00044032675,0.0012816701,0.0002894019,0.000019665087,0.000040277442,0.000030016696,0.004329397],"genre_scores_gemma":[0.035087824,0.9572977,0.0014095223,0.0016147296,0.00071705895,0.000039589013,0.0001358706,0.000006176396,0.0036915012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987495,0.000031158124,0.000015182303,0.000018228602,0.000046075962,0.000014431952],"domain_scores_gemma":[0.99993956,0.000020852882,0.000016457081,0.0000016310762,0.000013030584,0.0000084766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002864081,0.00024662193,0.00047527178,0.0006424231,0.00015239515,0.00030459443,0.00024462177,0.000468479,0.0019590857],"category_scores_gemma":[0.00029025134,0.00007462501,0.00031498613,0.0003841454,0.00019106477,0.00025746555,0.00025632075,0.0012642376,0.00072866504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047640936,0.00022919099,0.00038598728,0.005485596,0.00011188843,0.00070657284,0.000075419826,0.00035168216,0.013497055,0.0034965172,0.022151139,0.9530325],"study_design_scores_gemma":[0.0004198571,0.0010699119,0.0043121763,0.0026448672,0.0002630106,0.0066856835,0.00005726107,0.00037156008,0.0044547576,0.003287335,0.97639686,0.000036731897],"about_ca_topic_score_codex":0.00055122183,"about_ca_topic_score_gemma":0.0014478314,"teacher_disagreement_score":0.0019590857,"about_ca_system_score_codex":0.00027499214,"about_ca_system_score_gemma":0.00027169212,"threshold_uncertainty_score":0.006553769},"labels":[],"label_agreement":null},{"id":"W3109227879","doi":"10.2217/imt-2020-0265","title":"Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Eosinophilia; Medicine; Eosinophil; Melanoma; Immunotherapy; Internal medicine; Immunology; Retrospective cohort study; Gastroenterology; Oncology; Cancer research; Cancer; Asthma","score_opus":0.006064718479399405,"score_gpt":0.21165744942955636,"score_spread":0.20559273095015695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109227879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862087,0.0009482129,0.000115678195,0.000023588977,0.0000061864803,0.000004176046,0.00007262592,0.0000020244518,0.00020661949],"genre_scores_gemma":[0.99967635,0.00012238607,0.000056232482,0.0000070794454,0.000011316256,0.0000017113364,0.000071629125,4.6292072e-7,0.000052809257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998317,0.0000628852,0.00002077184,0.00003036047,0.000021463626,0.00003287104],"domain_scores_gemma":[0.9992142,0.00019245996,0.0003831493,0.000036039655,0.00006169537,0.00011238837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004831849,0.0001920996,0.00023109205,0.0003517805,0.00015485917,0.00027501993,0.00010763996,0.00023221695,0.0008283984],"category_scores_gemma":[0.0012521477,0.0000860333,0.00018973983,0.000348516,0.00014059215,0.00023466884,0.00018117385,0.00028807312,0.00013250032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039034974,0.00001715648,0.9965209,0.000009158704,0.000018781082,0.00008952368,0.000009688218,0.00004981736,0.00052231754,0.0000093192,0.000035150108,0.0023277628],"study_design_scores_gemma":[0.00001665347,0.00034037777,0.9976012,0.000008866837,0.000051299136,0.00082788145,0.00005514259,0.00038152144,0.00034588948,0.000033167613,0.0003346515,0.0000033516508],"about_ca_topic_score_codex":0.00023394234,"about_ca_topic_score_gemma":0.0003728159,"teacher_disagreement_score":0.0008283984,"about_ca_system_score_codex":0.00008531965,"about_ca_system_score_gemma":0.00010702658,"threshold_uncertainty_score":0.0027711987},"labels":[],"label_agreement":null},{"id":"W3199359059","doi":"10.2217/imt-2021-0133","title":"Immunoregulatory T cell Epitope Peptides for the Treatment of Allergic Disease","year":2021,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Regeneron Pharmaceuticals","keywords":"Epitope; Immunology; Disease; Medicine; Immunotherapy; Epitope mapping; Antibody; Immune system; Pathology","score_opus":0.04693637287601039,"score_gpt":0.33266512176056745,"score_spread":0.28572874888455707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199359059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009700078,0.9991248,0.000056798144,0.00008004233,0.00010989512,0.0000058721416,0.000012635027,0.0000047448957,0.0005082485],"genre_scores_gemma":[0.0007239313,0.9985967,0.00010795756,0.00010820287,0.0000831886,0.00000728431,0.000026115566,0.000001096636,0.0003455439],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983394,0.000037144484,0.0000232077,0.000024301937,0.000062466934,0.000018878778],"domain_scores_gemma":[0.9998379,0.000084458065,0.000027133692,0.0000057937755,0.000031767668,0.00001288175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043675513,0.00080062356,0.0012054254,0.0019156658,0.00019350761,0.000714607,0.00062263006,0.0008489677,0.005080278],"category_scores_gemma":[0.00050945266,0.00014687233,0.00078261795,0.001440847,0.00026463848,0.0006961842,0.0005385181,0.0015663338,0.0018042835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110920846,0.00010267663,0.00010327312,0.04344665,0.0002143124,0.0001578522,0.0000472042,0.00029356152,0.002384566,0.002080124,0.01974048,0.93131846],"study_design_scores_gemma":[0.000058657188,0.00016514871,0.0009489687,0.010667676,0.0004030481,0.001183933,0.00004864433,0.00008752232,0.0006003515,0.0016523285,0.98416775,0.000015920512],"about_ca_topic_score_codex":0.0006274795,"about_ca_topic_score_gemma":0.0010085554,"teacher_disagreement_score":0.005080278,"about_ca_system_score_codex":0.00033145017,"about_ca_system_score_gemma":0.0006457991,"threshold_uncertainty_score":0.016995251},"labels":[],"label_agreement":null},{"id":"W3210787730","doi":"10.2217/imt-2021-0068","title":"Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System","year":2021,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Adverse effect; Adverse Event Reporting System; Common Terminology Criteria for Adverse Events; Internal medicine; Ipilimumab; Oncology; Cancer; Immunotherapy; Nivolumab; Etiology; MedDRA; Kidney cancer; Pharmacovigilance","score_opus":0.010245077100603362,"score_gpt":0.2668065637972968,"score_spread":0.25656148669669343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210787730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986747,0.0044276332,0.0017942656,0.0004978869,0.000030058252,0.00009826825,0.0039402572,0.0000473356,0.0024171933],"genre_scores_gemma":[0.9978986,0.00034220435,0.00052088074,0.00010250585,0.000033112134,0.000029167924,0.0009102712,0.0000043728674,0.0001589869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952663,0.0015278864,0.0013163073,0.0005278708,0.0010748988,0.00028661493],"domain_scores_gemma":[0.938675,0.018528493,0.038158346,0.001186917,0.002667079,0.0007840861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040082694,0.00017016259,0.0003373422,0.0016764986,0.00020545031,0.0005473614,0.00025193486,0.00031761083,0.0026283844],"category_scores_gemma":[0.019881109,0.00010583964,0.00072446704,0.0019513469,0.00021181688,0.00047978704,0.0003920031,0.00054423296,0.00018720173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019714278,0.000021455218,0.9960098,0.000042988937,0.00011621921,0.000047218706,0.00000917304,0.00012925277,0.00016670974,0.000021698004,0.00017615901,0.0030621337],"study_design_scores_gemma":[0.000019231538,0.00018779833,0.99674404,0.00003794255,0.00009608098,0.0008286142,0.000041598276,0.0008192754,0.00029363256,0.000038729326,0.00088570896,0.0000073221145],"about_ca_topic_score_codex":0.0019095071,"about_ca_topic_score_gemma":0.0021102298,"teacher_disagreement_score":0.0040082694,"about_ca_system_score_codex":0.00041984595,"about_ca_system_score_gemma":0.00055659265,"threshold_uncertainty_score":0.021197975},"labels":[],"label_agreement":null},{"id":"W4282831736","doi":"10.2217/imt-2021-0250","title":"No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors","year":2022,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Immune system; Immune checkpoint; Immunotherapy; Retrospective cohort study; Cancer; Population; Immunology","score_opus":0.037653132573444666,"score_gpt":0.35211722116296235,"score_spread":0.3144640885895177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282831736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978149,0.00093009614,0.00019153702,0.000070412156,0.000019154515,0.000009488613,0.00022108857,0.0000037030165,0.0007396043],"genre_scores_gemma":[0.9995553,0.00008998085,0.0000647792,0.000034505734,0.000015607053,0.0000049499095,0.00016830768,0.0000019451975,0.000064561675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993424,0.0002083086,0.00008775136,0.00011921112,0.00016386795,0.000078334306],"domain_scores_gemma":[0.9911204,0.002943202,0.003994298,0.0004954849,0.0005934654,0.00085308123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016592148,0.00017426163,0.00036965465,0.00042049182,0.0002274904,0.0004843225,0.00023820535,0.00031609798,0.0019417837],"category_scores_gemma":[0.006419268,0.000138659,0.00049127726,0.0005401562,0.00026972746,0.00031522135,0.00030081705,0.000620315,0.00019189421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063605316,0.000019215458,0.9975418,0.00001377174,0.00009471223,0.000037025027,0.0000079537585,0.000033168297,0.00029896508,0.000012406752,0.00003250555,0.0012724806],"study_design_scores_gemma":[0.000021002192,0.0004481707,0.9985885,0.000007667559,0.00010361083,0.00033586094,0.000025496596,0.00012953232,0.00012282202,0.00003417902,0.00017970525,0.000003403387],"about_ca_topic_score_codex":0.00036228914,"about_ca_topic_score_gemma":0.0006429578,"teacher_disagreement_score":0.0019417837,"about_ca_system_score_codex":0.000198497,"about_ca_system_score_gemma":0.0003564257,"threshold_uncertainty_score":0.008774877},"labels":[],"label_agreement":null},{"id":"W4322617905","doi":"10.2217/imt-2022-0210","title":"Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Aplastic anemia; Medicine; Pembrolizumab; Anemia; Immunology; Globulin; Immunotherapy; Internal medicine; Immune system; Gastroenterology; Bone marrow","score_opus":0.03739182895557941,"score_gpt":0.37282529568210915,"score_spread":0.33543346672652974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322617905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043347967,0.998315,0.0000922294,0.0002392235,0.00014466199,0.000005822177,0.000018936185,0.0000058474006,0.0007448284],"genre_scores_gemma":[0.002625295,0.9963728,0.000190764,0.00030760467,0.00021552622,0.0000050392464,0.000031534033,0.0000017328805,0.0002498303],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9997619,0.00003815802,0.00007449719,0.00003938371,0.00006633681,0.000019704243],"domain_scores_gemma":[0.9995073,0.00027705447,0.000116063224,0.000013743452,0.000059985952,0.000025956053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034377634,0.0007733827,0.0014718111,0.0042572604,0.00042243217,0.0008765758,0.00077854656,0.0011703745,0.0027845255],"category_scores_gemma":[0.0009528052,0.00026853583,0.0007969703,0.0037620936,0.0004262993,0.0011963083,0.0004610544,0.0009666719,0.0008998377],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012724852,0.00014845085,0.0015658098,0.0900104,0.0007201897,0.034506064,0.00036199807,0.0004333021,0.0030121058,0.0019122252,0.04306726,0.824135],"study_design_scores_gemma":[0.000054390082,0.00021089407,0.0062055653,0.0463696,0.002342959,0.25761658,0.00060708734,0.00026325605,0.0012091544,0.002591414,0.6824395,0.00008961707],"about_ca_topic_score_codex":0.0012320904,"about_ca_topic_score_gemma":0.0021898064,"teacher_disagreement_score":0.0042572604,"about_ca_system_score_codex":0.000424085,"about_ca_system_score_gemma":0.0010538845,"threshold_uncertainty_score":0.009315133},"labels":[],"label_agreement":null},{"id":"W4375855360","doi":"10.2217/imt-2023-0062","title":"Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology","score_opus":0.01778521998774822,"score_gpt":0.26715033747022876,"score_spread":0.24936511748248053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375855360","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037071628,0.87144154,0.0024316912,0.06586492,0.01984846,0.0020412384,0.015885437,0.00028941283,0.018490147],"genre_scores_gemma":[0.015522337,0.8157609,0.005064058,0.09637483,0.03381699,0.0029392352,0.015768493,0.00022188785,0.014531279],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715555,0.0010389765,0.00081095105,0.00019481394,0.0006500503,0.00014957858],"domain_scores_gemma":[0.9900254,0.004599314,0.0022432695,0.00017960426,0.0024116454,0.000540778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006345713,0.0010158796,0.0031645151,0.0013098851,0.00037938272,0.003743597,0.0011812206,0.0019307744,0.011481584],"category_scores_gemma":[0.009939693,0.00049404183,0.003791616,0.0017727063,0.00041382312,0.0018445206,0.0007859104,0.003344798,0.0046614106],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078252265,0.00040451006,0.0016932184,0.09394056,0.00259891,0.00031863668,0.00020537474,0.00048622448,0.0013467001,0.0013619699,0.45039517,0.43942356],"study_design_scores_gemma":[0.007619461,0.006431348,0.009846078,0.05572244,0.005776972,0.00066566735,0.00025945585,0.00029387083,0.0008387431,0.00178741,0.9106083,0.00015027012],"about_ca_topic_score_codex":0.0016367806,"about_ca_topic_score_gemma":0.0022749808,"teacher_disagreement_score":0.011481584,"about_ca_system_score_codex":0.0010917312,"about_ca_system_score_gemma":0.0029417847,"threshold_uncertainty_score":0.03840971},"labels":[],"label_agreement":null},{"id":"W4376640915","doi":"10.2217/imt-2022-0139","title":"Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Circadian rhythm; Medicine; Melanoma; Immune system; Immune checkpoint; Association (psychology); Oncology; Internal medicine; Immunotherapy; Immunology; Cancer research; Psychology","score_opus":0.017196116946273547,"score_gpt":0.3009920710369966,"score_spread":0.28379595409072306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376640915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745804,0.001752224,0.00028747818,0.000034718596,0.000017921404,0.000005503977,0.00013481698,0.0000049922282,0.00030441655],"genre_scores_gemma":[0.99952924,0.00021382562,0.000090300266,0.000013458249,0.000011998575,0.0000031718378,0.00008183555,0.0000015051256,0.000054620592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980015,0.000059959137,0.000018333161,0.000052254516,0.000033110813,0.000036191777],"domain_scores_gemma":[0.99868745,0.00023652671,0.0008094429,0.00008724597,0.00008023759,0.000099062054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005791305,0.00013014495,0.00018140356,0.00017109924,0.00013484752,0.00031637264,0.00011064715,0.00012537326,0.00080099254],"category_scores_gemma":[0.0015680178,0.000095708885,0.00022258119,0.00022902974,0.00010606788,0.00015635404,0.00016775636,0.00024678424,0.00008749232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016777174,0.000058939157,0.9829441,0.000036617417,0.00010853956,0.00004171265,0.000041554904,0.00019561619,0.0023241453,0.000026846243,0.0001626309,0.012381571],"study_design_scores_gemma":[0.000018116443,0.00038487147,0.99829847,0.0000062197946,0.000046101515,0.00015312489,0.00003151331,0.00028788726,0.00041311086,0.00002387704,0.0003338156,0.000002903506],"about_ca_topic_score_codex":0.00076922367,"about_ca_topic_score_gemma":0.0010771541,"teacher_disagreement_score":0.00080099254,"about_ca_system_score_codex":0.00020799015,"about_ca_system_score_gemma":0.0001897147,"threshold_uncertainty_score":0.0030627847},"labels":[],"label_agreement":null},{"id":"W4383186917","doi":"10.2217/imt-2023-0069","title":"A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pfizer","keywords":"Alopecia areata; Medicine; Dermatology; Pediatrics","score_opus":0.012510771235180951,"score_gpt":0.2805351663317076,"score_spread":0.26802439509652665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383186917","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007339736,0.4516825,0.0018778212,0.26343393,0.06516072,0.0020732114,0.02671517,0.0011921739,0.18052469],"genre_scores_gemma":[0.027458657,0.3721315,0.0034312168,0.3396577,0.070086114,0.0027669496,0.021742037,0.00029718998,0.16242866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996501,0.00010237054,0.00010227247,0.000032277818,0.00007400469,0.000039033563],"domain_scores_gemma":[0.99812263,0.00070917,0.00034519646,0.000019199364,0.00054223364,0.0002616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004925111,0.00062341354,0.001427025,0.0007468741,0.00041314887,0.0011198582,0.0007646391,0.0018615297,0.06271464],"category_scores_gemma":[0.0031534203,0.00021884071,0.0008541991,0.0006006071,0.00016094065,0.0011615023,0.0003841073,0.0020513223,0.019816292],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034929512,0.00008343908,0.0002892191,0.0023541215,0.000025281808,0.00024021439,0.000030066758,0.000051562885,0.00030816664,0.00016383402,0.9087676,0.087337136],"study_design_scores_gemma":[0.00034153357,0.0006908692,0.0035999299,0.004045906,0.0000922672,0.0011088781,0.000095186806,0.0000662978,0.00015516675,0.00025371098,0.98952407,0.000026149126],"about_ca_topic_score_codex":0.0021415856,"about_ca_topic_score_gemma":0.0041639674,"teacher_disagreement_score":0.06271464,"about_ca_system_score_codex":0.00074788183,"about_ca_system_score_gemma":0.00082683534,"threshold_uncertainty_score":0.20980138},"labels":[],"label_agreement":null},{"id":"W4383872841","doi":"10.2217/imt-2022-0257","title":"An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Dosing; Lung cancer; Adverse effect; Internal medicine; Cancer; Retrospective cohort study; Toxicity; Gastroenterology; Immunotherapy","score_opus":0.03164804547800199,"score_gpt":0.40218010515864516,"score_spread":0.3705320596806432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970048,0.0011051148,0.00032424988,0.00012521577,0.00001204028,0.00007224147,0.00034513554,0.000005700697,0.0010055188],"genre_scores_gemma":[0.99899954,0.00017362447,0.00029514218,0.000106336636,0.000014684373,0.000032374784,0.0003006555,0.0000017633444,0.00007602276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846613,0.00068375055,0.00019058392,0.00022059218,0.00034341126,0.000095606505],"domain_scores_gemma":[0.9951675,0.0013664232,0.0023288573,0.00026891768,0.00047400364,0.00039429546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004455603,0.00016765739,0.0003824293,0.00029567734,0.0001749846,0.0005399514,0.00035738028,0.00034172725,0.0008592473],"category_scores_gemma":[0.007134546,0.00010648419,0.00031549076,0.00039241085,0.00019658862,0.0006389563,0.0004641743,0.00051360583,0.00011107306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012178009,0.0006947236,0.9241141,0.00013431079,0.00023191533,0.00008507817,0.00014947029,0.0011561757,0.0017543368,0.000097332595,0.00045375823,0.058950733],"study_design_scores_gemma":[0.00047325142,0.017079534,0.97606546,0.000057582194,0.00011786727,0.00041622084,0.0001580601,0.0017528449,0.00094763545,0.00008312374,0.0028353683,0.000013114061],"about_ca_topic_score_codex":0.0006305532,"about_ca_topic_score_gemma":0.0007053212,"teacher_disagreement_score":0.004455603,"about_ca_system_score_codex":0.0007027807,"about_ca_system_score_gemma":0.00049601914,"threshold_uncertainty_score":0.023563743},"labels":[],"label_agreement":null},{"id":"W4384662972","doi":"10.2217/imt-2023-0012","title":"Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Ulcerative colitis; Tofacitinib; Medicine; Colitis; Drug; Inflammation; Internal medicine; Immunology; Pharmacology; Disease","score_opus":0.04020959227294852,"score_gpt":0.3431351967940178,"score_spread":0.3029256045210693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384662972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001609326,0.9982734,0.00009142045,0.00017235722,0.0001951395,0.000005572154,0.000015355248,0.000008958602,0.0010768045],"genre_scores_gemma":[0.0012199833,0.9972625,0.00016008773,0.00025662556,0.0001606654,0.000008411027,0.000043282776,0.0000025581337,0.0008859034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998878,0.000019768051,0.000016117572,0.000019605537,0.000042933,0.000013764677],"domain_scores_gemma":[0.99988186,0.0000503854,0.000022703418,0.000003565873,0.000025739031,0.000015750724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034752267,0.00066198315,0.0009950267,0.0016214402,0.00021742145,0.00062323856,0.00069563807,0.00072476745,0.0037220127],"category_scores_gemma":[0.00040939337,0.00017644104,0.00048120393,0.0011664274,0.00027695074,0.0006455,0.0004627445,0.0017360763,0.0023047556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013104627,0.00006648313,0.00009691595,0.008725191,0.00009124647,0.00021603878,0.000029753235,0.00020531827,0.0012362248,0.001360529,0.02784734,0.959994],"study_design_scores_gemma":[0.000073369745,0.00013174604,0.0007359786,0.0029152276,0.00016159298,0.002086175,0.00002661187,0.000090190326,0.00045883766,0.0010921657,0.9922131,0.000014992836],"about_ca_topic_score_codex":0.00059522776,"about_ca_topic_score_gemma":0.0014886588,"teacher_disagreement_score":0.0037220127,"about_ca_system_score_codex":0.00035066684,"about_ca_system_score_gemma":0.00049639,"threshold_uncertainty_score":0.012451351},"labels":[],"label_agreement":null},{"id":"W4386591643","doi":"10.2217/imt-2023-0039","title":"Association Between Age and Efficacy of First-Line Immunotherapy-Based Combination Therapies for Mrcc: A Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Renal cell carcinoma; Sunitinib; Hazard ratio; Internal medicine; Kidney cancer; Immunotherapy; Oncology; Cancer; Confidence interval","score_opus":0.15708852634186113,"score_gpt":0.3821562660851957,"score_spread":0.22506773974333458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386591643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054245195,0.99325377,0.00033817816,0.00014739363,0.00010901725,0.00012553266,0.00035802287,0.000012962445,0.00023069402],"genre_scores_gemma":[0.23783875,0.7569402,0.0019552475,0.00088044506,0.00035421873,0.00061288726,0.0009895005,0.000025967262,0.0004028564],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956529,0.002238667,0.001034813,0.00048066129,0.0004159856,0.00017689573],"domain_scores_gemma":[0.99067163,0.0067563048,0.0015066717,0.00026789022,0.0006471995,0.00015032613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008207904,0.0020285954,0.012420626,0.0036057797,0.00045239518,0.0022236272,0.0011534106,0.0016066073,0.0032567745],"category_scores_gemma":[0.016670229,0.00091457623,0.0344684,0.003842891,0.0003653153,0.0011538129,0.00090931717,0.001694087,0.0002739893],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004616326,0.000045166194,0.006825969,0.23394212,0.73238605,0.000103679886,0.000054048094,0.0008321127,0.00031389485,0.00013073036,0.0008373739,0.019912453],"study_design_scores_gemma":[0.00070144073,0.00025055453,0.004736033,0.0117467595,0.98045427,0.000079843565,0.000024178422,0.00026435047,0.000097721386,0.00016407367,0.0014650943,0.000015578787],"about_ca_topic_score_codex":0.004670034,"about_ca_topic_score_gemma":0.010026346,"teacher_disagreement_score":0.012420626,"about_ca_system_score_codex":0.001613579,"about_ca_system_score_gemma":0.0019867101,"threshold_uncertainty_score":0.043408036},"labels":[],"label_agreement":null},{"id":"W4389951978","doi":"10.2217/imt-2023-0201","title":"Epicutaneous Immunotherapy with Viaskin Peanut in toddlers: a plain language summary","year":2023,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Genentech; UnitedHealth Group; Thermo Fisher Scientific; Food Allergy Research and Education","keywords":"Immunotherapy; Oral immunotherapy; Medicine; Psychology; Immunology; Immune system","score_opus":0.01674315307908023,"score_gpt":0.2877756399452742,"score_spread":0.27103248686619397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389951978","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038930809,0.81929994,0.0009536316,0.13406856,0.024083821,0.00043600847,0.001984375,0.0001388425,0.015141749],"genre_scores_gemma":[0.017889444,0.8025277,0.0021000772,0.12435928,0.0367985,0.00059531245,0.0019716965,0.00007547062,0.013682482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883956,0.0003873918,0.0004338175,0.00006279735,0.00019009256,0.000086469634],"domain_scores_gemma":[0.9938792,0.0026365253,0.0011914731,0.00008075048,0.0019157329,0.000296362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022765973,0.00065997714,0.0014089093,0.0011229059,0.00035349606,0.002226964,0.00065305387,0.0014635588,0.009505097],"category_scores_gemma":[0.008838186,0.00026154317,0.0010846877,0.0008129749,0.00043099833,0.0012903676,0.00055857125,0.0022898624,0.0034769399],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011581187,0.00030026768,0.0022791915,0.019389806,0.0002063559,0.0018199454,0.00024723605,0.00019281464,0.0012371835,0.0014633223,0.6230771,0.34862864],"study_design_scores_gemma":[0.00052117626,0.00200698,0.008883581,0.028311342,0.00052912865,0.0029776222,0.0005303886,0.00012338159,0.00072875124,0.001093813,0.95421964,0.000074128104],"about_ca_topic_score_codex":0.004314508,"about_ca_topic_score_gemma":0.0040669246,"teacher_disagreement_score":0.009505097,"about_ca_system_score_codex":0.0015253476,"about_ca_system_score_gemma":0.0022981798,"threshold_uncertainty_score":0.031797707},"labels":[],"label_agreement":null},{"id":"W4391882558","doi":"10.2217/imt-2023-0293","title":"Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Medicine; Rheumatoid arthritis; Crohn's disease; Internal medicine; Janus kinase; Disease; Oncology; Malignancy; Cytokine","score_opus":0.029763640887804577,"score_gpt":0.3346496295131636,"score_spread":0.30488598862535904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391882558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018485672,0.9978896,0.000079373385,0.00019977582,0.00022950918,0.00000560617,0.000028299834,0.000010201979,0.0013727793],"genre_scores_gemma":[0.0012741548,0.99705267,0.00012084095,0.00024067574,0.0001520522,0.000007748434,0.00007050567,0.0000025526342,0.001078908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988973,0.00001879416,0.000015003872,0.000017387774,0.000043539032,0.000015489686],"domain_scores_gemma":[0.9998965,0.00004176317,0.000019167293,0.0000028410734,0.000025087635,0.0000146776965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003074032,0.000571087,0.0010169777,0.0014481485,0.00020926444,0.00070731604,0.00066764717,0.0006730318,0.0046406034],"category_scores_gemma":[0.00040010345,0.0001464701,0.00047399732,0.001113332,0.00020319609,0.0006202597,0.0004771372,0.0015607836,0.002563965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011859791,0.000047908386,0.00008535512,0.009621139,0.00009667714,0.00017585466,0.000028657209,0.00027770447,0.00087156886,0.0015488653,0.04041302,0.9467146],"study_design_scores_gemma":[0.000056177752,0.000095654395,0.0005621214,0.003150346,0.00014589769,0.0013659516,0.000026437549,0.00010932403,0.0003056399,0.001049188,0.9931197,0.000013552933],"about_ca_topic_score_codex":0.000607093,"about_ca_topic_score_gemma":0.0015630741,"teacher_disagreement_score":0.0046406034,"about_ca_system_score_codex":0.00037410844,"about_ca_system_score_gemma":0.00051048683,"threshold_uncertainty_score":0.015524387},"labels":[],"label_agreement":null},{"id":"W4394873105","doi":"10.2217/imt-2023-0219","title":"Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Crohn's disease; Internal medicine; Monoclonal antibody; Monoclonal; Disease; Immunology; Antibody","score_opus":0.016375999755439376,"score_gpt":0.3122671550094165,"score_spread":0.29589115525397713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394873105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000246143,0.9978376,0.0001740963,0.0007062729,0.0001610272,0.00005231074,0.000043616532,0.0000073420133,0.0007716233],"genre_scores_gemma":[0.0041165673,0.99333644,0.0011780314,0.0008189805,0.000119834076,0.00008538051,0.0000962645,0.0000030669094,0.00024541692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985948,0.0004892764,0.00048908836,0.00012781967,0.00023470343,0.000064222266],"domain_scores_gemma":[0.9983224,0.0008036067,0.00044453543,0.000023734017,0.00035786052,0.000047883306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021022013,0.0007339543,0.0021713772,0.0047942274,0.00033434236,0.0014779881,0.001123693,0.0013939051,0.0021738366],"category_scores_gemma":[0.0037932177,0.0003560652,0.0014721153,0.0037057896,0.00057877647,0.0016464533,0.00087788183,0.001061357,0.00069328625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033376957,0.000037814138,0.0009238931,0.25366396,0.0006850656,0.00019831226,0.0002797215,0.0005053576,0.0009539673,0.0037436502,0.017638281,0.72103626],"study_design_scores_gemma":[0.00039066872,0.00031144838,0.004720531,0.46708578,0.005874854,0.0019498558,0.00045811676,0.0004937188,0.0006537955,0.0035404658,0.5144531,0.00006765409],"about_ca_topic_score_codex":0.0031831355,"about_ca_topic_score_gemma":0.0061045964,"teacher_disagreement_score":0.0047942274,"about_ca_system_score_codex":0.0018864925,"about_ca_system_score_gemma":0.004453552,"threshold_uncertainty_score":0.013687491},"labels":[],"label_agreement":null},{"id":"W4403247213","doi":"10.1080/1750743x.2024.2408216","title":"Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Kingston Health Sciences Centre; University of Ottawa","funders":"","keywords":"Medicine; Immunotherapy; Allergen immunotherapy; Omalizumab; Desensitization (medicine); Allergen; Immunology; Dosing; Allergy; Intensive care medicine; Immunoglobulin E; Immune system; Internal medicine; Antibody","score_opus":0.1560110096589077,"score_gpt":0.3240526827005774,"score_spread":0.1680416730416697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403247213","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011859232,0.99857616,0.0001336631,0.00015965433,0.000121761535,0.0000070354704,0.000011526947,0.0000053271833,0.0008662889],"genre_scores_gemma":[0.00077553483,0.9982141,0.0002687775,0.00019913346,0.000073491596,0.000008489682,0.000022963517,0.0000017247539,0.00043586516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968207,0.00006855639,0.00004384254,0.000049007194,0.00013036544,0.000026140237],"domain_scores_gemma":[0.9996675,0.00020999827,0.0000387884,0.000013193361,0.00005584416,0.000014711608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060855196,0.00081813935,0.0012777225,0.003105744,0.0002896299,0.0010741748,0.00065739895,0.0009649258,0.004682047],"category_scores_gemma":[0.0007495668,0.00023982242,0.001106519,0.0023375677,0.00048337103,0.0015625473,0.0006960247,0.0019714797,0.0014672637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007141897,0.00012131698,0.00012788466,0.06260954,0.00020742888,0.00016704056,0.0001272552,0.00031806488,0.0023622774,0.0065178745,0.014166826,0.9132031],"study_design_scores_gemma":[0.000026057602,0.00013632207,0.0008755372,0.013460391,0.00025402362,0.0010632828,0.0000977058,0.00009289002,0.00063331804,0.0032261033,0.98011553,0.00001876302],"about_ca_topic_score_codex":0.0010376722,"about_ca_topic_score_gemma":0.0021498073,"teacher_disagreement_score":0.004682047,"about_ca_system_score_codex":0.0005590226,"about_ca_system_score_gemma":0.0011970709,"threshold_uncertainty_score":0.015662968},"labels":[],"label_agreement":null},{"id":"W4405111359","doi":"10.1080/1750743x.2024.2436346","title":"Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review &amp; meta-analysis","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Radiosensitizer; Oncology; Cisplatin; Head and neck squamous-cell carcinoma; Immunotherapy; Meta-analysis; Internal medicine; Radiation therapy; Standard of care; Head and neck cancer; Chemotherapy; Cancer","score_opus":0.07829244723347409,"score_gpt":0.3949451119656623,"score_spread":0.3166526647321882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405111359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045513255,0.9939745,0.00040681902,0.00015230064,0.00011062084,0.0002508158,0.00032911653,0.000018918408,0.00020550088],"genre_scores_gemma":[0.22457461,0.76930714,0.0022437281,0.0009870173,0.00025259124,0.0014277702,0.00069268275,0.000033503118,0.0004808962],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.992374,0.0041023553,0.0018424982,0.0007124733,0.00073220074,0.00023643901],"domain_scores_gemma":[0.9843337,0.0112745045,0.0029253936,0.00042063784,0.00085589604,0.00018985342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011587598,0.0022171512,0.015259323,0.004304633,0.00051102845,0.0028736058,0.0018255711,0.0020453657,0.0034257143],"category_scores_gemma":[0.027425637,0.0012309022,0.02993161,0.006014493,0.0007242113,0.0014367144,0.0012720592,0.001599765,0.0002838057],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022563513,0.000028459042,0.002744725,0.3638902,0.6212152,0.00009973144,0.000060147562,0.0005068779,0.00016681149,0.00011795957,0.0005941063,0.008319483],"study_design_scores_gemma":[0.0007716833,0.00019116292,0.002494552,0.020840757,0.9739042,0.00007386791,0.000029586736,0.00017667511,0.00008683089,0.00015247583,0.0012625227,0.000015595175],"about_ca_topic_score_codex":0.0072303633,"about_ca_topic_score_gemma":0.015624035,"teacher_disagreement_score":0.015259323,"about_ca_system_score_codex":0.002533807,"about_ca_system_score_gemma":0.002779759,"threshold_uncertainty_score":0.06128186},"labels":[],"label_agreement":null},{"id":"W4405200272","doi":"10.1080/1750743x.2024.2436838","title":"Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Research Canada; Dalhousie University","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; American Academy of Allergy Asthma and Immunology","keywords":"Adverse effect; Medicine; Immune system; Melanoma; Pembrolizumab; Incidence (geometry); Meta-analysis; Oncology; Ipilimumab; Internal medicine; Immunotherapy; Immunology; Cancer research","score_opus":0.03227925669359021,"score_gpt":0.35404011530669366,"score_spread":0.32176085861310344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405200272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036250756,0.99477816,0.00030456495,0.00015927677,0.000099810204,0.00017834171,0.0005918532,0.0000154617,0.0002474174],"genre_scores_gemma":[0.12644914,0.86927915,0.0013122834,0.0007957293,0.00023483585,0.0007816009,0.0008218121,0.000020757669,0.0003046879],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936026,0.0029908775,0.0017458874,0.00068482955,0.00074430264,0.00023147464],"domain_scores_gemma":[0.98523986,0.010647618,0.0025488785,0.0003258904,0.0010686382,0.00016909408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009009881,0.002197735,0.013340246,0.004804581,0.00051898323,0.0024798021,0.0015833275,0.0019005355,0.003582186],"category_scores_gemma":[0.02259679,0.001192848,0.03423636,0.005634282,0.00049513555,0.0011195847,0.0011607552,0.0016489555,0.00025756305],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020190035,0.000030540967,0.0036247205,0.50191313,0.47513333,0.00013566962,0.00005568959,0.00066917524,0.0001941814,0.00012328169,0.0009330993,0.015168268],"study_design_scores_gemma":[0.000638445,0.00020693323,0.0044302964,0.036258385,0.9558287,0.00014019935,0.00003291924,0.00021320005,0.00010814803,0.00018291338,0.0019359563,0.000023937931],"about_ca_topic_score_codex":0.006169708,"about_ca_topic_score_gemma":0.012125925,"teacher_disagreement_score":0.013340246,"about_ca_system_score_codex":0.0021110475,"about_ca_system_score_gemma":0.003048574,"threshold_uncertainty_score":0.047649384},"labels":[],"label_agreement":null},{"id":"W4407081442","doi":"10.1080/1750743x.2025.2455922","title":"Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer","year":2025,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Thyroid cancer; Follicular phase; Medicine; Follicular cell; Cancer research; Follicular thyroid cancer; Thyroid; Oncology; Immunology; Cancer; Internal medicine; Papillary thyroid cancer","score_opus":0.04647064221397133,"score_gpt":0.32639970456052403,"score_spread":0.2799290623465527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407081442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008366462,0.9992531,0.00005143777,0.00012311256,0.000080679616,0.000003562251,0.000010018201,0.0000024421383,0.000391959],"genre_scores_gemma":[0.0005566964,0.9989484,0.00009279149,0.00013461446,0.00006489867,0.0000046691853,0.00001832974,6.856418e-7,0.00017896504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983406,0.000041503205,0.000029861354,0.000025218236,0.000053107862,0.0000161494],"domain_scores_gemma":[0.99973696,0.00016134525,0.00003282348,0.0000055231744,0.000050710263,0.000012654011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052369485,0.0005059263,0.0011115458,0.0016647015,0.0001984635,0.00078954385,0.0005816167,0.0008087446,0.0028290516],"category_scores_gemma":[0.0007443275,0.00016680428,0.00068099133,0.001335622,0.00023678488,0.0007985336,0.00047409738,0.001335635,0.00082894013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104582214,0.00005977231,0.00014473751,0.046053044,0.0002102515,0.00017230955,0.00006886616,0.0003953997,0.001660962,0.0025006374,0.015582424,0.93304694],"study_design_scores_gemma":[0.000043254648,0.00019350127,0.00110956,0.017505474,0.000492968,0.001545241,0.000084266896,0.00013823243,0.00059159857,0.0021311028,0.9761439,0.000020967927],"about_ca_topic_score_codex":0.0010087538,"about_ca_topic_score_gemma":0.002092455,"teacher_disagreement_score":0.0028290516,"about_ca_system_score_codex":0.0005095884,"about_ca_system_score_gemma":0.0010070446,"threshold_uncertainty_score":0.009464085},"labels":[],"label_agreement":null},{"id":"W4407377433","doi":"10.1080/1750743x.2025.2457931","title":"Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"McGill University; McMaster University; AstraZeneca","keywords":"Benralizumab; Asthma; Medicine; Eosinophilic; Internal medicine; Pathology; Eosinophil; Mepolizumab","score_opus":0.0220841725104322,"score_gpt":0.33048536828880365,"score_spread":0.30840119577837144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407377433","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021111386,0.69580334,0.004569758,0.12716791,0.043965477,0.013154702,0.07191423,0.00053087174,0.021782285],"genre_scores_gemma":[0.13613507,0.60149634,0.017879993,0.06007491,0.069486775,0.03875357,0.062748514,0.00071635266,0.01270855],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.97789943,0.012089641,0.0051176287,0.0011300376,0.0029983432,0.0007649378],"domain_scores_gemma":[0.90941,0.0429156,0.026735237,0.0025191798,0.013899892,0.0045200577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025890049,0.0012243394,0.0034637197,0.0022050354,0.00047372447,0.004996343,0.0012812536,0.0027176787,0.015048239],"category_scores_gemma":[0.07286982,0.00080246705,0.0047541778,0.0048368913,0.0005430352,0.0019474104,0.0016580666,0.0029973525,0.0032608388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046149556,0.0006583709,0.011046619,0.1599701,0.011471686,0.00027086434,0.00043417746,0.0010590059,0.00091768487,0.0017737574,0.46633813,0.29991],"study_design_scores_gemma":[0.055018857,0.012677989,0.08594324,0.19059375,0.029188734,0.0008526538,0.0006691736,0.00091296725,0.00149199,0.0032008674,0.6189403,0.00050954183],"about_ca_topic_score_codex":0.0014497456,"about_ca_topic_score_gemma":0.0015876506,"teacher_disagreement_score":0.025890049,"about_ca_system_score_codex":0.0023887225,"about_ca_system_score_gemma":0.0063660406,"threshold_uncertainty_score":0.13692135},"labels":[],"label_agreement":null},{"id":"W4408003542","doi":"10.1080/1750743x.2025.2464528","title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Amgen","keywords":"Atopic dermatitis; Medicine; Dermatology; Rocket (weapon); Engineering; Aeronautics","score_opus":0.020515252635573036,"score_gpt":0.3718269398653076,"score_spread":0.3513116872297346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408003542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93571746,0.011166745,0.003138912,0.0031115874,0.0007094993,0.019711984,0.010379898,0.00093593274,0.015127917],"genre_scores_gemma":[0.9258702,0.0075771026,0.008996492,0.005267182,0.0004057168,0.018792825,0.017117102,0.00023489913,0.015738394],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948704,0.00024406819,0.000022849032,0.000066405664,0.000071379305,0.00010820662],"domain_scores_gemma":[0.99946815,0.00008497094,0.00011651459,0.000045832785,0.00007929193,0.00020521309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029984785,0.00134752,0.0011195516,0.00046372612,0.00041842597,0.001118778,0.0010346599,0.0011165475,0.008013604],"category_scores_gemma":[0.0010711409,0.0003428434,0.0014307608,0.0003416582,0.0006235951,0.0009161784,0.00044915552,0.0031181774,0.0015835622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42332605,0.08509511,0.011517305,0.0034766032,0.003232424,0.00062065426,0.00046951242,0.006148054,0.09167109,0.0018869293,0.06849275,0.3040635],"study_design_scores_gemma":[0.59491336,0.3309817,0.020499099,0.00034147993,0.0012863227,0.0010770459,0.0001666335,0.0038384853,0.013673766,0.00086476817,0.032282215,0.00007519569],"about_ca_topic_score_codex":0.0009515012,"about_ca_topic_score_gemma":0.003095512,"teacher_disagreement_score":0.008013604,"about_ca_system_score_codex":0.0009210706,"about_ca_system_score_gemma":0.0021162843,"threshold_uncertainty_score":0.026808202},"labels":[],"label_agreement":null},{"id":"W4409178690","doi":"10.1080/1750743x.2025.2485012","title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; McMaster University; Pancreas Centre (Canada); University Health Network; Kingston Health Sciences Centre; Canadian Partnership Against Cancer","funders":"Canadian Cancer Society Research Institute; AstraZeneca","keywords":"Immune system; Medicine; Immunology; Oncology; Cancer research","score_opus":0.012069763549505152,"score_gpt":0.29527718584675666,"score_spread":0.2832074222972515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409178690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80438024,0.14383216,0.010881721,0.0006930732,0.0005934174,0.0021115518,0.031934544,0.00041686176,0.0051564076],"genre_scores_gemma":[0.98935586,0.0028409045,0.0016325857,0.00022453202,0.00016176848,0.0006545072,0.004513605,0.000061620594,0.00055452745],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98045725,0.011504907,0.0022579092,0.0027884315,0.0022296996,0.00076183974],"domain_scores_gemma":[0.9808405,0.010493413,0.004249186,0.0028603023,0.0011846372,0.00037191968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018163271,0.001117087,0.005949385,0.0025838285,0.0003149711,0.0016223073,0.00082057546,0.00094016554,0.002793096],"category_scores_gemma":[0.022875618,0.0004942137,0.010534528,0.003611254,0.00040924526,0.00066845195,0.00091794034,0.0007589152,0.00023646181],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098609835,0.00015662918,0.21907511,0.007492169,0.61538553,0.00036956943,0.00016501299,0.0050604274,0.0031975918,0.00024225771,0.004586235,0.04565964],"study_design_scores_gemma":[0.009714143,0.006551212,0.39079598,0.000636129,0.5721816,0.00058949465,0.00016602901,0.0065128296,0.002027145,0.00081005564,0.009843255,0.00017213204],"about_ca_topic_score_codex":0.0075810356,"about_ca_topic_score_gemma":0.011486216,"teacher_disagreement_score":0.018163271,"about_ca_system_score_codex":0.0011615017,"about_ca_system_score_gemma":0.0014213889,"threshold_uncertainty_score":0.09605777},"labels":[],"label_agreement":null},{"id":"W4409810942","doi":"10.1080/1750743x.2025.2491295","title":"Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects","year":2025,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myasthenia gravis; Medicine; Intensive care medicine; Immunology","score_opus":0.023138706098924072,"score_gpt":0.35242130160104707,"score_spread":0.329282595502123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409810942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008075677,0.99934965,0.000037101647,0.00017573083,0.000080411715,0.000002140024,0.0000064738174,0.0000033679892,0.0002644266],"genre_scores_gemma":[0.00042995348,0.9989549,0.00009732145,0.00019063558,0.00008866941,0.0000039613246,0.000013380978,8.8928635e-7,0.0002203626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999851,0.00003246127,0.000025473966,0.000026663944,0.000049105493,0.000015255742],"domain_scores_gemma":[0.9997627,0.00012651629,0.000036884514,0.0000061111195,0.000047829715,0.000020070656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058399217,0.0006386087,0.0013197007,0.0017564395,0.00020116809,0.0007953949,0.000638205,0.0009616869,0.0033951614],"category_scores_gemma":[0.000581426,0.0002047213,0.0007596348,0.0015503212,0.00032425032,0.0011084704,0.00043927794,0.0016328815,0.0011269217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014235602,0.00007755855,0.000119353674,0.028677937,0.00014914415,0.00018825004,0.000065156324,0.00027335473,0.0015048668,0.00257337,0.023830807,0.94239783],"study_design_scores_gemma":[0.000093768744,0.00021894024,0.0010191002,0.010550862,0.00041565212,0.0017727116,0.00007761842,0.00014130426,0.00033694177,0.0021519908,0.9831982,0.000022953525],"about_ca_topic_score_codex":0.0008853164,"about_ca_topic_score_gemma":0.0018854799,"teacher_disagreement_score":0.0033951614,"about_ca_system_score_codex":0.00049600453,"about_ca_system_score_gemma":0.0009132591,"threshold_uncertainty_score":0.011357963},"labels":[],"label_agreement":null},{"id":"W4410303297","doi":"10.1080/1750743x.2025.2493039","title":"Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medac; Cilag; Mylan; Celgene; Biogen; Gilead Sciences; Chugai Pharmaceutical; Celltrion; Sanofi; Eli Lilly and Company; AstraZeneca; Edwards Lifesciences; Amgen","keywords":"Biosimilar; Etanercept; Medicine; Plain language; Pharmacology; Internal medicine; Intensive care medicine; Oncology; Physical therapy; Rheumatoid arthritis; Linguistics","score_opus":0.02248146023747329,"score_gpt":0.35650275953216726,"score_spread":0.334021299294694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410303297","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11152762,0.42145893,0.014278711,0.21449767,0.023126295,0.015349478,0.13036655,0.0009878137,0.06840699],"genre_scores_gemma":[0.37578657,0.28804177,0.047587205,0.1504003,0.022725895,0.02492643,0.06830609,0.0005031395,0.021722484],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.97567505,0.012225643,0.006782444,0.0006837709,0.00419986,0.00043330854],"domain_scores_gemma":[0.93164086,0.036201015,0.014310137,0.001436831,0.015226773,0.001184334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022326898,0.0007704099,0.0019437409,0.0014020076,0.00047096782,0.0033240814,0.0006865646,0.0018027939,0.012871258],"category_scores_gemma":[0.06506791,0.00042806767,0.002345991,0.001572484,0.00049606594,0.0018361466,0.0009808732,0.002333993,0.0034231888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01683914,0.00083706895,0.027624886,0.056471318,0.003592049,0.00043403503,0.0013434538,0.00075786083,0.0015499806,0.0020444714,0.47038934,0.41811642],"study_design_scores_gemma":[0.0117773,0.012860215,0.10580187,0.047086306,0.005678808,0.0013468312,0.0019264797,0.0008754641,0.0028537717,0.0029931979,0.8063291,0.00047072396],"about_ca_topic_score_codex":0.002392235,"about_ca_topic_score_gemma":0.0037347493,"teacher_disagreement_score":0.022326898,"about_ca_system_score_codex":0.0017669542,"about_ca_system_score_gemma":0.003227664,"threshold_uncertainty_score":0.11807734},"labels":[],"label_agreement":null},{"id":"W4411260891","doi":"10.1080/1750743x.2025.2518913","title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Head and neck; Toxicity; Basal cell; Oncology; Head and neck squamous-cell carcinoma; Radiation therapy; Internal medicine; Carcinoma; Head and neck cancer; Surgery; Cancer; Immunotherapy","score_opus":0.013062482689831033,"score_gpt":0.2701643034079915,"score_spread":0.2571018207181605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411260891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989016,0.00035334277,0.00009189805,0.0000523888,0.0000030505048,0.000030172452,0.000089552814,0.000003700896,0.0004741267],"genre_scores_gemma":[0.9992206,0.00032222577,0.000126602,0.000056755125,0.000007688556,0.000010146766,0.00010416243,0.0000034446464,0.00014828415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995504,0.000103888415,0.00006640544,0.000063528976,0.00011726384,0.000098497934],"domain_scores_gemma":[0.99854517,0.00023525872,0.0005755449,0.00006082059,0.00025327972,0.00032991715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060792296,0.0001905043,0.00028217447,0.0004019446,0.00072275475,0.0007478775,0.00028339768,0.00021887451,0.0008294374],"category_scores_gemma":[0.0021479393,0.00015856227,0.00026730157,0.00077076716,0.00040208254,0.00026851537,0.0006020651,0.00031498523,0.00015774369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022202685,0.00013226536,0.9797188,0.0000611638,0.00004211154,0.0021918,0.0012282626,0.00017067263,0.0007827097,0.0000240176,0.0003332225,0.015093012],"study_design_scores_gemma":[0.000046980436,0.0013654554,0.97969085,0.00007723996,0.000099644996,0.010602857,0.003746904,0.00046667474,0.0010820221,0.000053049203,0.002742988,0.000025289286],"about_ca_topic_score_codex":0.0330644,"about_ca_topic_score_gemma":0.08985957,"teacher_disagreement_score":0.0330644,"about_ca_system_score_codex":0.0029251473,"about_ca_system_score_gemma":0.0021586388,"threshold_uncertainty_score":0.06574386},"labels":[],"label_agreement":null},{"id":"W4411899191","doi":"10.1080/1750743x.2025.2527574","title":"Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?","year":2025,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; McMaster University","funders":"","keywords":"Medicine; Melanoma; Dissection (medical); Lymph node; Immunotherapy; Neoadjuvant therapy; Surgery; Pathology; Immune system; Internal medicine; Immunology; Cancer research; Cancer","score_opus":0.007626434994813059,"score_gpt":0.28104288107949543,"score_spread":0.27341644608468235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411899191","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013129767,0.029878289,0.00027068192,0.05889491,0.9084488,0.00004757473,0.00008827991,0.000075342774,0.0021648372],"genre_scores_gemma":[0.00075571035,0.019519743,0.0002203209,0.06242518,0.91011804,0.000047037684,0.000056136592,0.000036474547,0.0068212934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805427,0.0005439022,0.00033723732,0.0002255985,0.00073658145,0.000102454695],"domain_scores_gemma":[0.9936474,0.0038068586,0.0003950652,0.00011566459,0.001342155,0.00069282966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005146142,0.002087863,0.0024920732,0.0013321857,0.001306358,0.002923283,0.002700841,0.009364804,0.0054445476],"category_scores_gemma":[0.012775504,0.0008209043,0.0019289098,0.00089155737,0.0014048818,0.0032004972,0.00071240903,0.019825574,0.0062219054],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016437507,0.000019859048,0.000038064467,0.0005986357,0.00004387737,0.0001263528,0.000012039817,0.00004900498,0.00010914429,0.00039958957,0.97881407,0.019624995],"study_design_scores_gemma":[0.0004586686,0.0001478139,0.0005692268,0.0014729114,0.00021997024,0.00066713104,0.000044131753,0.0003706404,0.00019622709,0.0015899929,0.994224,0.000039177394],"about_ca_topic_score_codex":0.0017738728,"about_ca_topic_score_gemma":0.0055956375,"teacher_disagreement_score":0.009364804,"about_ca_system_score_codex":0.002209219,"about_ca_system_score_gemma":0.001951042,"threshold_uncertainty_score":0.02721572},"labels":[],"label_agreement":null},{"id":"W4413876847","doi":"10.1080/1750743x.2025.2545172","title":"Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Cardiovascular Prevention and Rehabilitation; Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Medicine; Antibody; Immunology; Dermatology","score_opus":0.017410696122824466,"score_gpt":0.38352179729230657,"score_spread":0.3661111011694821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413876847","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019330125,0.74445224,0.005111448,0.09921911,0.02205195,0.011094357,0.016503403,0.00061347755,0.081623845],"genre_scores_gemma":[0.07497201,0.63830423,0.01708539,0.13679408,0.029522408,0.008563447,0.020347245,0.00028304322,0.07412823],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9980124,0.00089546724,0.00041089658,0.000103381135,0.00047790917,0.00009984425],"domain_scores_gemma":[0.995736,0.0012794082,0.0005878139,0.00011280346,0.0019016117,0.00038232276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062054987,0.0008646396,0.0015624274,0.0008391416,0.0003984565,0.0020323463,0.0008032512,0.0019331943,0.016528394],"category_scores_gemma":[0.0054569375,0.00032116452,0.0023545038,0.0007784038,0.0002548098,0.001145993,0.00045194692,0.0022650687,0.0048492667],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009861502,0.0012709935,0.0011560537,0.016948149,0.0008076927,0.0004890518,0.00010281306,0.00024552076,0.0036798627,0.001441527,0.4225033,0.5414935],"study_design_scores_gemma":[0.017542098,0.0144480085,0.005871419,0.012483662,0.0023239236,0.0015795697,0.00011344233,0.00036359142,0.0024209642,0.00139012,0.94136745,0.00009571588],"about_ca_topic_score_codex":0.0009156338,"about_ca_topic_score_gemma":0.0016541627,"teacher_disagreement_score":0.016528394,"about_ca_system_score_codex":0.0008771155,"about_ca_system_score_gemma":0.0016229902,"threshold_uncertainty_score":0.055293024},"labels":[],"label_agreement":null},{"id":"W4415765951","doi":"10.1080/1750743x.2025.2578164","title":"Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Pancreas Centre (Canada); Queen's University; McMaster University; Juravinski Cancer Centre; Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; AstraZeneca","keywords":"Serotonergic; Pooled analysis; Context (archaeology); Clinical trial; Meta-analysis; Patient data; Cancer; Immune system","score_opus":0.04188281269778614,"score_gpt":0.3426528544300924,"score_spread":0.30077004173230626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415765951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7646656,0.18624137,0.003742042,0.0006927894,0.00024155289,0.0021716699,0.038100883,0.00020693846,0.00393715],"genre_scores_gemma":[0.97736734,0.0077381167,0.0014625693,0.0003404924,0.00015186038,0.0009369066,0.011537856,0.00005331772,0.0004114995],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9816569,0.009053274,0.0025184357,0.002230668,0.0036049613,0.0009357003],"domain_scores_gemma":[0.9770364,0.010326195,0.0068627116,0.0020673356,0.0028968803,0.000810428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020888146,0.001532525,0.007490114,0.003155992,0.00058916135,0.001602661,0.0009943751,0.0009420032,0.0015617432],"category_scores_gemma":[0.02268659,0.0005888369,0.0078124106,0.005976173,0.00057239924,0.000597848,0.000811695,0.00077514834,0.00012896887],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14124669,0.00017134647,0.32510975,0.008532564,0.45834285,0.00040160617,0.0002867192,0.0052000848,0.0025451167,0.0001927385,0.0062491987,0.051721364],"study_design_scores_gemma":[0.014543873,0.0061533144,0.6147339,0.00066261954,0.351478,0.0004796305,0.00017453778,0.0023353323,0.0009223658,0.0003487869,0.007983614,0.0001839735],"about_ca_topic_score_codex":0.04489815,"about_ca_topic_score_gemma":0.09690899,"teacher_disagreement_score":0.04489815,"about_ca_system_score_codex":0.003293989,"about_ca_system_score_gemma":0.0038405694,"threshold_uncertainty_score":0.11046839},"labels":[],"label_agreement":null}]}